refid,design_f_lab,study,study_l,study_l_w_linked,study_id,arm_id,drug,drug_f,drug_recode,drug_recode_abbr,drug_study,arm_n,arm_proph_meds,none,proph_history,proph_med_pre,proph_med_induct,proph_med_intra,proph_med_postop,proph_med_unspec,dexmed,dexmed_loading,dexmed_maintain,dexmed_maintain_low,dexmed_maintain_up,dexmed_postdose,ketamine,ketamine_dose,ketamine_dose_iv,ket_postdose,melatonin,melatonin_dose,melatonin_days,ramelteon,ramelteon_dose,ramelteon_numberdoses,gabapentin,gabapentin_dose,gabapentin_numberdoses,ulinastatin,ulinastatin_dose,ulinastatin_numberdoses,notes,multiple_kq,drug_kq5,control_desc_kq5,other_spec,interv_desc,control_desc
10,Randomized Clinical Trial,Zhang 2018a,[Zhang 2018a](evidence_tables.html#10),[Zhang 2018a](evidence_tables.html#10),Zhang 2018a-1,1,,,,,,190,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,Randomized Clinical Trial,Zhang 2018a,[Zhang 2018a](evidence_tables.html#10),[Zhang 2018a](evidence_tables.html#10),Zhang 2018a-2,2,,,,,,189,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,Randomized Clinical Trial,Li 2021a,[Li 2021a](evidence_tables.html#17),[Li 2021a](evidence_tables.html#17),Li 2021a-1,1,,,,,,272,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,Randomized Clinical Trial,Li 2021a,[Li 2021a](evidence_tables.html#17),[Li 2021a](evidence_tables.html#17),Li 2021a-2,2,,,,,,272,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,Prospective Cohort,Konishi 2018,[Konishi 2018](evidence_tables.html#22),[Konishi 2018](evidence_tables.html#22),Konishi 2018-1,1,,,,,,121,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,Prospective Cohort,Konishi 2018,[Konishi 2018](evidence_tables.html#22),[Konishi 2018](evidence_tables.html#22),Konishi 2018-2,2,,,,,,171,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,Randomized Clinical Trial,Li 2017,[Li 2017](evidence_tables.html#24),[Li 2017](evidence_tables.html#24),Li 2017-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,143,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9% sodium chloride 2 ml; Saline administered during anesthesia and early postoperative period
24,Randomized Clinical Trial,Li 2017,[Li 2017](evidence_tables.html#24),[Li 2017](evidence_tables.html#24),Li 2017-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,142,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,dexmedetomidine,0.6,0.4,,,0.1,,,,,,,,,,,,,,,,,,,,,,"dexmedetomidine hydrochloride 200 μg /2 ml; Study drugs were diluted with normal saline to 50 ml before administration, for dexmedetomidine the final concentration was 4 μg/ml; In the operating room, study drug infusion was
started once the intravenous access was established, firstly at a rate of [0.9 × kg] ml/h (i.e.,
0.6 μg/kg for dexmedetomidine) for 10 minutes, then at a rate of [0.1 × kg] ml/h (i.e.,
0.4 μg x kg-1 x h-1 for dexmedetomidine) until the end of surgery",
69,Randomized Clinical Trial,Huyan 2019,[Huyan 2019](evidence_tables.html#69),[Huyan 2019](evidence_tables.html#69),Huyan 2019-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,173,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Normal saline 50 ml, 20 min before surgery, stopped 30 min before surgery"
69,Randomized Clinical Trial,Huyan 2019,[Huyan 2019](evidence_tables.html#69),[Huyan 2019](evidence_tables.html#69),Huyan 2019-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,173,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.5,0.1,,,,,,,,,,,,,,,,,,,,,,,,,,
103,Retrospective Cohort,Chuich 2019,[Chuich 2019](evidence_tables.html#103),[Chuich 2019](evidence_tables.html#103),Chuich 2019-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,209,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propofol,,Propofol-based sedation in addition to general anesthesia intraoperatively
103,Retrospective Cohort,Chuich 2019,[Chuich 2019](evidence_tables.html#103),[Chuich 2019](evidence_tables.html#103),Chuich 2019-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,69,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,0.193,0.078,0.308,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine-based sedation in addition to general anesthesia intraoperatively,
118,Retrospective Cohort,Mueller 2020a,[Mueller 2020a](evidence_tables.html#118),[Mueller 2020a](evidence_tables.html#118),Mueller 2020a-1,1,,,,,Dexmedetomidine,82,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
118,Retrospective Cohort,Mueller 2020a,[Mueller 2020a](evidence_tables.html#118),[Mueller 2020a](evidence_tables.html#118),Mueller 2020a-2,2,,,,,Dexmedetomidine,529,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
120,Nonrandomized Trial,Xie 2018,[Xie 2018](evidence_tables.html#120),[Xie 2018](evidence_tables.html#120),Xie 2018-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,70,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50 ml saline at induction and infusion
120,Nonrandomized Trial,Xie 2018,[Xie 2018](evidence_tables.html#120),[Xie 2018](evidence_tables.html#120),Xie 2018-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,70,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,
132,Retrospective Cohort,Oh 2019,[Oh 2019](evidence_tables.html#132),[Oh 2019](evidence_tables.html#132),Oh 2019-1,1,,,,,Dexmedetomidine,1477,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
132,Retrospective Cohort,Oh 2019,[Oh 2019](evidence_tables.html#132),[Oh 2019](evidence_tables.html#132),Oh 2019-2,2,,,,,Dexmedetomidine,1395,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
149,Before-After/Time Series,Indrakusuma 2015,[Indrakusuma 2015](evidence_tables.html#149),[Indrakusuma 2015](evidence_tables.html#149),Indrakusuma 2015-1,1,,,,,Dexmedetomidine,222,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
149,Before-After/Time Series,Indrakusuma 2015,[Indrakusuma 2015](evidence_tables.html#149),[Indrakusuma 2015](evidence_tables.html#149),Indrakusuma 2015-2,2,,,,,Dexmedetomidine,221,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,Randomized Clinical Trial,Qin 2019,[Qin 2019](evidence_tables.html#150),[Qin 2019](evidence_tables.html#150),Qin 2019-1,1,,,,,Dexmedetomidine,52,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,Randomized Clinical Trial,Qin 2019,[Qin 2019](evidence_tables.html#150),[Qin 2019](evidence_tables.html#150),Qin 2019-2,2,,,,,Dexmedetomidine,52,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,Prospective Cohort,Deiner 2015,[Deiner 2015](evidence_tables.html#155),[Deiner 2015](evidence_tables.html#155),Deiner 2015-1,1,,,,,Dexmedetomidine,34,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,Prospective Cohort,Deiner 2015,[Deiner 2015](evidence_tables.html#155),[Deiner 2015](evidence_tables.html#155),Deiner 2015-2,2,,,,,Dexmedetomidine,43,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,Randomized Clinical Trial,Xu 2020,[Xu 2020](evidence_tables.html#158),[Xu 2020](evidence_tables.html#158),Xu 2020-1,1,,,,,Dexmedetomidine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,Randomized Clinical Trial,Xu 2020,[Xu 2020](evidence_tables.html#158),[Xu 2020](evidence_tables.html#158),Xu 2020-2,2,,,,,Dexmedetomidine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,Randomized Clinical Trial,Xu 2020,[Xu 2020](evidence_tables.html#158),[Xu 2020](evidence_tables.html#158),Xu 2020-3,3,,,,,Dexmedetomidine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
181,Randomized Clinical Trial,Hudetz 2009a,[Hudetz 2009a](evidence_tables.html#181),[Hudetz 2009a](evidence_tables.html#181),Hudetz 2009a-1,1,None,Control,None,None,Ketamine,26,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nonsurgical controls
181,Randomized Clinical Trial,Hudetz 2009a,[Hudetz 2009a](evidence_tables.html#181),[Hudetz 2009a](evidence_tables.html#181),Hudetz 2009a-2,2,Placebo,Control,Placebo,Plac,Ketamine,26,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IV bolus saline during anesthetic induction
181,Randomized Clinical Trial,Hudetz 2009a,[Hudetz 2009a](evidence_tables.html#181),[Hudetz 2009a](evidence_tables.html#181),Hudetz 2009a-3,3,Ketamine,Ketamine,Ketamine,Ket,Ketamine,26,kq6_proph_meds,,,,proph_med_induct,,,,,,,,,,ketamine,0.5,,,,,,,,,,,,,,,,,,,,IV bolus ketamine (0.5 mg/kg) during anesthetic induction,
208,Randomized Clinical Trial,Harsten 2013,[Harsten 2013](evidence_tables.html#208),[Harsten 2013](evidence_tables.html#208),Harsten 2013-1,1,,,,,Ketamine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
208,Randomized Clinical Trial,Harsten 2013,[Harsten 2013](evidence_tables.html#208),[Harsten 2013](evidence_tables.html#208),Harsten 2013-2,2,,,,,Ketamine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
234,Retrospective Cohort,Jakobsen 2007,[Jakobsen 2007](evidence_tables.html#234),[Jakobsen 2007](evidence_tables.html#234),Jakobsen 2007-1,1,,,,,Ketamine,5325,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
234,Retrospective Cohort,Jakobsen 2007,[Jakobsen 2007](evidence_tables.html#234),[Jakobsen 2007](evidence_tables.html#234),Jakobsen 2007-2,2,,,,,Ketamine,5210,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
239,Randomized Clinical Trial,Carron 2007,[Carron 2007](evidence_tables.html#239),[Carron 2007](evidence_tables.html#239),Carron 2007-1,1,,,,,Ketamine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
239,Randomized Clinical Trial,Carron 2007,[Carron 2007](evidence_tables.html#239),[Carron 2007](evidence_tables.html#239),Carron 2007-2,2,,,,,Ketamine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
241,Randomized Clinical Trial,Mazul-Sunko 2010,[Mazul-Sunko 2010](evidence_tables.html#241),[Mazul-Sunko 2010](evidence_tables.html#241),Mazul-Sunko 2010-1,1,,,,,Ketamine,28,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
241,Randomized Clinical Trial,Mazul-Sunko 2010,[Mazul-Sunko 2010](evidence_tables.html#241),[Mazul-Sunko 2010](evidence_tables.html#241),Mazul-Sunko 2010-2,2,,,,,Ketamine,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
261,Randomized Clinical Trial,Lee 2018a,[Lee 2018a](evidence_tables.html#261),[Lee 2018a](evidence_tables.html#261),Lee 2018a-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,109,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10mL of saline 15 min before the end of surgery
261,Randomized Clinical Trial,Lee 2018a,[Lee 2018a](evidence_tables.html#261),[Lee 2018a](evidence_tables.html#261),Lee 2018a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,95,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,,0.2,0.7,,,,,,,,,,,,,,,,,,,,,,,1ug/kg bolus of dex followed by 0.2-0.7ug/kg/hr infusion from induction of anethesia to the end of surgery,
261,Randomized Clinical Trial,Lee 2018a,[Lee 2018a](evidence_tables.html#261),[Lee 2018a](evidence_tables.html#261),Lee 2018a-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,114,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,1,,,,,,,,,,,,,,,,,,,,,,,,,,1ug/kg diluted to a total volume of 10mL in saline (0.9%) over a 10 minute period 15 minutes before the end of surgery,
262,Randomized Clinical Trial,Purwar 2015,[Purwar 2015](evidence_tables.html#262),[Purwar 2015](evidence_tables.html#262),Purwar 2015-1,1,,,,,Dexmedetomidine,28,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
262,Randomized Clinical Trial,Purwar 2015,[Purwar 2015](evidence_tables.html#262),[Purwar 2015](evidence_tables.html#262),Purwar 2015-2,2,,,,,Dexmedetomidine,31,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
269,Randomized Clinical Trial,Harsten 2015,[Harsten 2015](evidence_tables.html#269),[Harsten 2015](evidence_tables.html#269),Harsten 2015-1,1,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
269,Randomized Clinical Trial,Harsten 2015,[Harsten 2015](evidence_tables.html#269),[Harsten 2015](evidence_tables.html#269),Harsten 2015-2,2,,,,,Dexmedetomidine,58,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
285,Randomized Clinical Trial,Tanaka 2017,[Tanaka 2017](evidence_tables.html#285),[Tanaka 2017](evidence_tables.html#285),Tanaka 2017-1,1,,,,,Dexmedetomidine,45,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
285,Randomized Clinical Trial,Tanaka 2017,[Tanaka 2017](evidence_tables.html#285),[Tanaka 2017](evidence_tables.html#285),Tanaka 2017-2,2,,,,,Dexmedetomidine,45,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
296,Randomized Clinical Trial,Salonia 2004,[Salonia 2004](evidence_tables.html#296),[Salonia 2004](evidence_tables.html#296),Salonia 2004-1,1,,,,,Dexmedetomidine,34,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
296,Randomized Clinical Trial,Salonia 2004,[Salonia 2004](evidence_tables.html#296),[Salonia 2004](evidence_tables.html#296),Salonia 2004-2,2,,,,,Dexmedetomidine,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
307,Randomized Clinical Trial,Nesek-Adam 2012,[Nesek-Adam 2012](evidence_tables.html#307),[Nesek-Adam 2012](evidence_tables.html#307),Nesek-Adam 2012-1,1,,,,,Dexmedetomidine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
307,Randomized Clinical Trial,Nesek-Adam 2012,[Nesek-Adam 2012](evidence_tables.html#307),[Nesek-Adam 2012](evidence_tables.html#307),Nesek-Adam 2012-2,2,,,,,Dexmedetomidine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
328,Randomized Clinical Trial,Zhang 2018b (prop),[Zhang 2018b](evidence_tables.html#328),[Zhang 2018b](evidence_tables.html#328),Zhang 2018b-1,1,Other,Control,Midazolam/propofol,Mid/Prop,Dexmedetomidine,30,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam and propofol,,Propofol (4ug/mL) by target controlled infusion. Midazolam (2-3mg) was injected.
328,Randomized Clinical Trial,Zhang 2018b (sevo),[Zhang 2018b](evidence_tables.html#328),[Zhang 2018b](evidence_tables.html#328),Zhang 2018b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.5,,,,,,,,,,,,,,,,,,,,,,,,,"Loading dose of 1ug/kg dex, infused continuously for 12 minutes. The loading dose was followed by a continuous IV infusion at a rate of 0.5ug/kg/hr. Propofol (4ug/mL) by target controlled infusion.",
328,Randomized Clinical Trial,Zhang 2018b (prop),[Zhang 2018b](evidence_tables.html#328),[Zhang 2018b](evidence_tables.html#328),Zhang 2018b-3,3,Other,Control,Midazolam/sevoflurane,Mid/Sevo,Dexmedetomidine,30,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam and sevoflurane,,Midazolam (2-3mg) was injected. Treated with sevoflurane 1 minimum alveolar concentration.
328,Randomized Clinical Trial,Zhang 2018b (sevo),[Zhang 2018b](evidence_tables.html#328),[Zhang 2018b](evidence_tables.html#328),Zhang 2018b-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.5,,,,,,,,,,,,,,,,,,,,,,,,,"Loading dose of 1ug/kg dex, infused continuously for 12 minutes. The loading dose was followed by a continuous IV infusion at a rate of 0.5ug/kg/hr.  Treated with sevoflurane 1 minimum alveolar concentration.",
329,Randomized Clinical Trial,Salonia 2006,[Salonia 2006](evidence_tables.html#329),[Salonia 2006](evidence_tables.html#329),Salonia 2006-1,1,,,,,Dexmedetomidine,34,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
329,Randomized Clinical Trial,Salonia 2006,[Salonia 2006](evidence_tables.html#329),[Salonia 2006](evidence_tables.html#329),Salonia 2006-2,2,,,,,Dexmedetomidine,28,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
329,Randomized Clinical Trial,Salonia 2006,[Salonia 2006](evidence_tables.html#329),[Salonia 2006](evidence_tables.html#329),Salonia 2006-3,3,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
329,Randomized Clinical Trial,Salonia 2006,[Salonia 2006](evidence_tables.html#329),[Salonia 2006](evidence_tables.html#329),Salonia 2006-4,4,,,,,Dexmedetomidine,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331,Randomized Clinical Trial,Nishikawa 2007a,[Nishikawa 2007a](evidence_tables.html#331),[Nishikawa 2007a](evidence_tables.html#331),Nishikawa 2007a-1,1,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331,Randomized Clinical Trial,Nishikawa 2007a,[Nishikawa 2007a](evidence_tables.html#331),[Nishikawa 2007a](evidence_tables.html#331),Nishikawa 2007a-2,2,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
332,Retrospective Cohort,Goins 2018,[Goins 2018](evidence_tables.html#332),[Goins 2018](evidence_tables.html#332),Goins 2018-1,1,,,,,Dexmedetomidine,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
332,Retrospective Cohort,Goins 2018,[Goins 2018](evidence_tables.html#332),[Goins 2018](evidence_tables.html#332),Goins 2018-2,2,,,,,Dexmedetomidine,84,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
335,Randomized Clinical Trial,van Norden 2021,[van Norden 2021](evidence_tables.html#335),[van Norden 2021](evidence_tables.html#335),van Norden 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,32,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.7 ug/kg saline
335,Randomized Clinical Trial,van Norden 2021,[van Norden 2021](evidence_tables.html#335),[van Norden 2021](evidence_tables.html#335),van Norden 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,28,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,0.7ug/kg of dex after induction,
376,Randomized Clinical Trial,Zangrillo 2011,[Zangrillo 2011](evidence_tables.html#376),[Zangrillo 2011](evidence_tables.html#376),Zangrillo 2011-1,1,,,,,Dexmedetomidine,44,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
376,Randomized Clinical Trial,Zangrillo 2011,[Zangrillo 2011](evidence_tables.html#376),[Zangrillo 2011](evidence_tables.html#376),Zangrillo 2011-2,2,,,,,Dexmedetomidine,44,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
383,Retrospective Cohort,Kishimoto 2018,[Kishimoto 2018](evidence_tables.html#383),[Kishimoto 2018](evidence_tables.html#383),Kishimoto 2018-1,1,,,,,Dexmedetomidine,5140,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
383,Retrospective Cohort,Kishimoto 2018,[Kishimoto 2018](evidence_tables.html#383),[Kishimoto 2018](evidence_tables.html#383),Kishimoto 2018-2,2,,,,,Dexmedetomidine,5140,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
385,Randomized Clinical Trial,Nishikawa 2004,[Nishikawa 2004](evidence_tables.html#385),[Nishikawa 2004](evidence_tables.html#385),Nishikawa 2004-1,1,,,,,Dexmedetomidine,25,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
385,Randomized Clinical Trial,Nishikawa 2004,[Nishikawa 2004](evidence_tables.html#385),[Nishikawa 2004](evidence_tables.html#385),Nishikawa 2004-2,2,,,,,Dexmedetomidine,25,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
397,Randomized Clinical Trial,Nishikawa 2007b,[Nishikawa 2007b](evidence_tables.html#397),[Nishikawa 2007b](evidence_tables.html#397),Nishikawa 2007b-1,1,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
397,Randomized Clinical Trial,Nishikawa 2007b,[Nishikawa 2007b](evidence_tables.html#397),[Nishikawa 2007b](evidence_tables.html#397),Nishikawa 2007b-2,2,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
447,Randomized Clinical Trial,Lindholm 2013,[Lindholm 2013](evidence_tables.html#447),[Lindholm 2013](evidence_tables.html#447),Lindholm 2013-1,1,,,,,Dexmedetomidine,97,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
447,Randomized Clinical Trial,Lindholm 2013,[Lindholm 2013](evidence_tables.html#447),[Lindholm 2013](evidence_tables.html#447),Lindholm 2013-2,2,,,,,Dexmedetomidine,96,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
534,Randomized Clinical Trial,Cai 2012,[Cai 2012](evidence_tables.html#534),[Cai 2012](evidence_tables.html#534),Cai 2012-1,1,,,,,Dexmedetomidine,1000,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
534,Randomized Clinical Trial,Cai 2012,[Cai 2012](evidence_tables.html#534),[Cai 2012](evidence_tables.html#534),Cai 2012-2,2,,,,,Dexmedetomidine,1000,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
555,Randomized Clinical Trial,Ommundsen 2018,[Ommundsen 2018](evidence_tables.html#555),[Ommundsen 2018](evidence_tables.html#555),Ommundsen 2018-1,1,,,,,Dexmedetomidine,63,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
555,Randomized Clinical Trial,Ommundsen 2018,[Ommundsen 2018](evidence_tables.html#555),[Ommundsen 2018](evidence_tables.html#555),Ommundsen 2018-2,2,,,,,Dexmedetomidine,53,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
602,Randomized Clinical Trial,Fan 2017,[Fan 2017](evidence_tables.html#602),[Fan 2017](evidence_tables.html#602),Fan 2017-1,1,Placebo,Control,Placebo,Plac,Melatonin,70,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1 oral pill 1 hour before bedtime day before surgery, then for 5 days consecutive postoperative days."
602,Randomized Clinical Trial,Fan 2017,[Fan 2017](evidence_tables.html#602),[Fan 2017](evidence_tables.html#602),Fan 2017-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,69,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,1,6,,,,,,,,,,,,,,,"1 oral pill 1 hour before bedtime day before surgery, then for 5 days consecutive postoperative days.",
658,Randomized Clinical Trial,Wongyingsinn 2020,[Wongyingsinn 2020](evidence_tables.html#658),[Wongyingsinn 2020](evidence_tables.html#658),Wongyingsinn 2020-1,1,,,,,Melatonin,18,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
658,Randomized Clinical Trial,Wongyingsinn 2020,[Wongyingsinn 2020](evidence_tables.html#658),[Wongyingsinn 2020](evidence_tables.html#658),Wongyingsinn 2020-2,2,,,,,Melatonin,18,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
693,Before-After/Time Series,Hokuto 2020,[Hokuto 2020](evidence_tables.html#693),[Hokuto 2020](evidence_tables.html#693),Hokuto 2020-1,1,None,Control,None,None,Ramelteon,186,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
693,Before-After/Time Series,Hokuto 2020,[Hokuto 2020](evidence_tables.html#693),[Hokuto 2020](evidence_tables.html#693),Hokuto 2020-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,120,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,8,4,,,,,,,,,,,,one dose day before surgery and on PODs 1-3,
737,Randomized Clinical Trial,Ornek 2010,[Ornek 2010](evidence_tables.html#737),[Ornek 2010](evidence_tables.html#737),Ornek 2010-1,1,,,,,Ramelteon,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
737,Randomized Clinical Trial,Ornek 2010,[Ornek 2010](evidence_tables.html#737),[Ornek 2010](evidence_tables.html#737),Ornek 2010-2,2,,,,,Ramelteon,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
741,Randomized Clinical Trial,Marcantonio 2001,[Marcantonio 2001](evidence_tables.html#741),[Marcantonio 2001](evidence_tables.html#741),Marcantonio 2001-1,1,,,,,Ramelteon,64,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
741,Randomized Clinical Trial,Marcantonio 2001,[Marcantonio 2001](evidence_tables.html#741),[Marcantonio 2001](evidence_tables.html#741),Marcantonio 2001-2,2,,,,,Ramelteon,62,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
742,Randomized Clinical Trial,Li 2019,[Li 2019](evidence_tables.html#742),[Li 2019](evidence_tables.html#742),Li 2019-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,55,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propofol,Combined spinal-epidural anesthesia with light sedation using propofol,propofol,,Combined spinal-epidural anesthesia with light sedation using propofol
742,Randomized Clinical Trial,Li 2019,[Li 2019](evidence_tables.html#742),[Li 2019](evidence_tables.html#742),Li 2019-2,2,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,54,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"one arm administered dexmedetomidine, KQ6",Midazolam,,,,
742,Randomized Clinical Trial,Li 2019,[Li 2019](evidence_tables.html#742),[Li 2019](evidence_tables.html#742),Li 2019-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,55,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,,,,,,,,,,,,,,,,,,,,,one arm administered midazolam which is a KQ5 intervention,Dexmedetomidine,,,"combined spinal-epidural anesthesia with light sedation using dexmedetomidine, dosage adjusted to BIS 70-85",
750,Nonrandomized Trial,Van Grootven 2016,[Van Grootven 2016](evidence_tables.html#750),[Van Grootven 2016](evidence_tables.html#750),Van Grootven 2016-1,1,,,,,Dexmedetomidine,62,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
750,Nonrandomized Trial,Van Grootven 2016,[Van Grootven 2016](evidence_tables.html#750),[Van Grootven 2016](evidence_tables.html#750),Van Grootven 2016-2,2,,,,,Dexmedetomidine,24,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
760,Randomized Clinical Trial,Hempenius 2013,[Hempenius 2013](evidence_tables.html#760),[Hempenius 2013](evidence_tables.html#760),Hempenius 2013-1,1,,,,,Dexmedetomidine,149,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
760,Randomized Clinical Trial,Hempenius 2013,[Hempenius 2013](evidence_tables.html#760),[Hempenius 2013](evidence_tables.html#760),Hempenius 2013-2,2,,,,,Dexmedetomidine,148,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
781,Randomized Clinical Trial,Silbert 2014,[Silbert 2014](evidence_tables.html#781),[Silbert 2014](evidence_tables.html#781),Silbert 2014-1,1,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
781,Randomized Clinical Trial,Silbert 2014,[Silbert 2014](evidence_tables.html#781),[Silbert 2014](evidence_tables.html#781),Silbert 2014-2,2,,,,,Dexmedetomidine,48,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
831,Randomized Clinical Trial,Rasmussen 2003,[Rasmussen 2003](evidence_tables.html#831),[Rasmussen 2003](evidence_tables.html#831),Rasmussen 2003-1,1,,,,,Dexmedetomidine,217,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
831,Randomized Clinical Trial,Rasmussen 2003,[Rasmussen 2003](evidence_tables.html#831),[Rasmussen 2003](evidence_tables.html#831),Rasmussen 2003-2,2,,,,,Dexmedetomidine,211,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
889,Randomized Clinical Trial,Chen 2020,[Chen 2020](evidence_tables.html#889),[Chen 2020](evidence_tables.html#889),Chen 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,45,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intraoperative saline infusion
889,Randomized Clinical Trial,Chen 2020,[Chen 2020](evidence_tables.html#889),[Chen 2020](evidence_tables.html#889),Chen 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,43,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.3,1,,,,,,,,,,,,,,,,,,,,,,,,,slow pumping dose of dexmedetomidine - 0.3 mcg/kg/h loading dose with 1 mcg/kg/h maintenance,
1117,Randomized Clinical Trial,Mansouri 2019,[Mansouri 2019](evidence_tables.html#1117),[Mansouri 2019](evidence_tables.html#1117),Mansouri 2019-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,given intraoperatively,,Placebo,Normal saline,,,Normal saline
1117,Randomized Clinical Trial,Mansouri 2019,[Mansouri 2019](evidence_tables.html#1117),[Mansouri 2019](evidence_tables.html#1117),Mansouri 2019-2,2,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam,,,,
1117,Randomized Clinical Trial,Mansouri 2019,[Mansouri 2019](evidence_tables.html#1117),[Mansouri 2019](evidence_tables.html#1117),Mansouri 2019-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,50,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,1,,,,,,,,,,,,,,,,,,,,,third study arm: 0.1 mg/kg of midazolam (benzo for KQ5),Dexmedetomidine,,,intravenously,
1134,Retrospective Cohort,Park 2020,[Park 2020](evidence_tables.html#1134),[Park 2020](evidence_tables.html#1134),Park 2020-1,1,,,,,Dexmedetomidine,386,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1134,Retrospective Cohort,Park 2020,[Park 2020](evidence_tables.html#1134),[Park 2020](evidence_tables.html#1134),Park 2020-2,2,,,,,Dexmedetomidine,100,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1140,Prospective Cohort,Juliebo 2009,[Juliebo 2009](evidence_tables.html#1140),[Juliebo 2009](evidence_tables.html#1140),Juliebo 2009-1,1,None,Control,None,None,Ketamine,119,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,None given.
1140,Prospective Cohort,Juliebo 2009,[Juliebo 2009](evidence_tables.html#1140),[Juliebo 2009](evidence_tables.html#1140),Juliebo 2009-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,68,kq6_proph_meds,,,,,proph_med_intra,,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,No dosing information provided,
1189,Before-After/Time Series,Adogwa 2017,[Adogwa 2017](evidence_tables.html#1189),[Adogwa 2017](evidence_tables.html#1189),Adogwa 2017-1,1,,,,,Ketamine,25,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1189,Before-After/Time Series,Adogwa 2017,[Adogwa 2017](evidence_tables.html#1189),[Adogwa 2017](evidence_tables.html#1189),Adogwa 2017-2,2,,,,,Ketamine,100,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1201,Randomized Clinical Trial,Watne 2014,[Watne 2014](evidence_tables.html#1201),[Watne 2014](evidence_tables.html#1201),Watne 2014-1,1,,,,,Ketamine,166,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1201,Randomized Clinical Trial,Watne 2014,[Watne 2014](evidence_tables.html#1201),[Watne 2014](evidence_tables.html#1201),Watne 2014-2,2,,,,,Ketamine,163,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263,Randomized Clinical Trial,Hempenius 2016,[Hempenius 2016](evidence_tables.html#1263),[Hempenius 2016](evidence_tables.html#1263) ([Hempenius 2013](evidence_tables.html#760)),Hempenius 2016-1,1,,,,,Ketamine,133,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1263,Randomized Clinical Trial,Hempenius 2016,[Hempenius 2016](evidence_tables.html#1263),[Hempenius 2016](evidence_tables.html#1263) ([Hempenius 2013](evidence_tables.html#760)),Hempenius 2016-2,2,,,,,Ketamine,127,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1267,Randomized Clinical Trial,Mei 2020a,[Mei 2020a](evidence_tables.html#1267),[Mei 2020a](evidence_tables.html#1267),Mei 2020a-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,183,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propofol dose (mg) mean and SD (342 ± 107),,,,Propofol: 0.8 to 1.0 mcg/mL,,Target controlled infusion (intraoperatively)
1267,Randomized Clinical Trial,Mei 2020a,[Mei 2020a](evidence_tables.html#1267),[Mei 2020a](evidence_tables.html#1267),Mei 2020a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,183,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.9,,0.1,0.5,,,,,,,,,,,,,,,,,,Dex dose (mg) mean and SD (105.9 ± 24.1),,,,,loading dose of dex 0.8 to 1.0 mcg/kg administered over 15 to 20 min followed by continuous infusion at 0.1 to 0.5 mcg/kg/h,
1288,Randomized Clinical Trial,Du 2019,[Du 2019](evidence_tables.html#1288),[Du 2019](evidence_tables.html#1288),Du 2019-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,20,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9% normal saline (NaCl) was given
1288,Randomized Clinical Trial,Du 2019,[Du 2019](evidence_tables.html#1288),[Du 2019](evidence_tables.html#1288),Du 2019-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,20,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,0.6,,,,,,,,,,,,,,,,,,,,,,,,,intravenous injection of dexmedetomidine 0.6 mcg/kg/h kept until the end of the surgery,
1294,Before-After/Time Series,Richter 2005,[Richter 2005](evidence_tables.html#1294),[Richter 2005](evidence_tables.html#1294),Richter 2005-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1294,Before-After/Time Series,Richter 2005,[Richter 2005](evidence_tables.html#1294),[Richter 2005](evidence_tables.html#1294),Richter 2005-2,2,,,,,Dexmedetomidine,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1313,Before-After/Time Series,Hall 2017,[Hall 2017](evidence_tables.html#1313),[Hall 2017](evidence_tables.html#1313),Hall 2017-1,1,,,,,Dexmedetomidine,5275,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1313,Before-After/Time Series,Hall 2017,[Hall 2017](evidence_tables.html#1313),[Hall 2017](evidence_tables.html#1313),Hall 2017-2,2,,,,,Dexmedetomidine,3878,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1320,Randomized Clinical Trial,Tzimas 2018,[Tzimas 2018](evidence_tables.html#1320),[Tzimas 2018](evidence_tables.html#1320),Tzimas 2018-1,1,,,,,Dexmedetomidine,33,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1320,Randomized Clinical Trial,Tzimas 2018,[Tzimas 2018](evidence_tables.html#1320),[Tzimas 2018](evidence_tables.html#1320),Tzimas 2018-2,2,,,,,Dexmedetomidine,37,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1332,Prospective Cohort,Wang 2021,[Wang 2021](evidence_tables.html#1332),[Wang 2021](evidence_tables.html#1332),Wang 2021-1,1,,,,,Dexmedetomidine,357,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1332,Prospective Cohort,Wang 2021,[Wang 2021](evidence_tables.html#1332),[Wang 2021](evidence_tables.html#1332),Wang 2021-2,2,,,,,Dexmedetomidine,357,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1335,Randomized Clinical Trial,Parker 2015,[Parker 2015](evidence_tables.html#1335),[Parker 2015](evidence_tables.html#1335),Parker 2015-1,1,,,,,Dexmedetomidine,164,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1335,Randomized Clinical Trial,Parker 2015,[Parker 2015](evidence_tables.html#1335),[Parker 2015](evidence_tables.html#1335),Parker 2015-2,2,,,,,Dexmedetomidine,158,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1400,Randomized Clinical Trial,Papaiannou 2005,[Papaiannou 2005](evidence_tables.html#1400),[Papaiannou 2005](evidence_tables.html#1400),Papaiannou 2005-1,1,,,,,Dexmedetomidine,28,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1400,Randomized Clinical Trial,Papaiannou 2005,[Papaiannou 2005](evidence_tables.html#1400),[Papaiannou 2005](evidence_tables.html#1400),Papaiannou 2005-2,2,,,,,Dexmedetomidine,19,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1419,Randomized Clinical Trial,Liu 2016 (MCI),[Liu 2016 (MCI)](evidence_tables.html#1419),[Liu 2016 (MCI)](evidence_tables.html#1419),Liu 2016-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,40,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Continuous IV infusion of saline after induction for duration of surgery
1419,Randomized Clinical Trial,Liu 2016 (MCI),[Liu 2016 (MCI)](evidence_tables.html#1419),[Liu 2016 (MCI)](evidence_tables.html#1419),Liu 2016-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,39,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,0.2,0.4,,,,,,,,,,,,,,,,,,,,,,,continuous IV infusion 0.2 to 0.4 mcg/kg/h dexmedetomidine without initial dose for duration of surgery,
1419,Randomized Clinical Trial,Liu 2016 (no MCI),[Liu 2016 (no MCI)](evidence_tables.html#1419),[Liu 2016 (no MCI)](evidence_tables.html#1419),Liu 2016-3,3,Placebo,Control,Placebo,Plac,Dexmedetomidine,58,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Continuous IV infusion of saline after induction for duration of surgery
1419,Randomized Clinical Trial,Liu 2016 (no MCI),[Liu 2016 (no MCI)](evidence_tables.html#1419),[Liu 2016 (no MCI)](evidence_tables.html#1419),Liu 2016-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,60,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,0.2,0.4,,,,,,,,,,,,,,,,,,,,,,,continuous IV infusion 0.2 to 0.4 mcg/kg/h dexmedetomidine without initial dose for duration of surgery,
1489,Randomized Clinical Trial,Zhang 2019a,[Zhang 2019a](evidence_tables.html#1489),[Zhang 2019a](evidence_tables.html#1489),Zhang 2019a-1,1,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1489,Randomized Clinical Trial,Zhang 2019a,[Zhang 2019a](evidence_tables.html#1489),[Zhang 2019a](evidence_tables.html#1489),Zhang 2019a-2,2,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1505,Randomized Clinical Trial,Hongyu 2019,[Hongyu 2019](evidence_tables.html#1505),[Hongyu 2019](evidence_tables.html#1505),Hongyu 2019-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1505,Randomized Clinical Trial,Hongyu 2019,[Hongyu 2019](evidence_tables.html#1505),[Hongyu 2019](evidence_tables.html#1505),Hongyu 2019-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1625,Randomized Clinical Trial,Wang 2020a,[Wang 2020a](evidence_tables.html#1625),[Wang 2020a](evidence_tables.html#1625),Wang 2020a-1,1,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam,,,,
1625,Randomized Clinical Trial,Wang 2020a,[Wang 2020a](evidence_tables.html#1625),[Wang 2020a](evidence_tables.html#1625),Wang 2020a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,20,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,1,,0.2,0.7,,,,,,,,,,,,,,,,,,"If Ramsay score .4, nurse increased the infusion rate up to a max of 1.0mcg/kg/h",,Dexmedetomidine,,,Received 1.0 mcg/kg of dexmedetomidine over a 10 min period and then continuously perfused (0.2-0.7 mcg/kg/h),
1735,Randomized Clinical Trial,Mei 2018,[Mei 2018](evidence_tables.html#1735),[Mei 2018](evidence_tables.html#1735),Mei 2018-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,148,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propofol,,"Target-controlled infusion of propofol, 0.8 to 1.0 ug/mL"
1735,Randomized Clinical Trial,Mei 2018,[Mei 2018](evidence_tables.html#1735),[Mei 2018](evidence_tables.html#1735),Mei 2018-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,148,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,0.9,,0.1,0.5,,,,,,,,,,,,,,,,,,,,,,,"bolus od dexmedetomidine at 0.8-1.0 ug/kg administered over 15-20 minutes, followed by an infusion of dex at 0.1-0.5ug/kg/hr",
1819,Randomized Clinical Trial,Gao 2020,[Gao 2020](evidence_tables.html#1819),[Gao 2020](evidence_tables.html#1819),Gao 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intravenous injection of saline at induction and through surgery (0.9% saline)
1819,Randomized Clinical Trial,Gao 2020,[Gao 2020](evidence_tables.html#1819),[Gao 2020](evidence_tables.html#1819),Gao 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,,0.3,0.5,,,,,,,,,,,,,,,,,,,,,,,intravenous injection of dexmedetomidine at induction and through surgery,
1847,Randomized Clinical Trial,Hudetz 2009b,[Hudetz 2009b](evidence_tables.html#1847),[Hudetz 2009b](evidence_tables.html#1847) ([Hudetz 2009a](evidence_tables.html#181)),Hudetz 2009b-1,1,Placebo,Control,Placebo,Plac,Ketamine,29,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IV bolus saline during anesthetic induction
1847,Randomized Clinical Trial,Hudetz 2009b,[Hudetz 2009b](evidence_tables.html#1847),[Hudetz 2009b](evidence_tables.html#1847) ([Hudetz 2009a](evidence_tables.html#181)),Hudetz 2009b-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,29,kq6_proph_meds,,,,proph_med_induct,,,,,,,,,,ketamine,0.5,,,,,,,,,,,,,,,,,,,,IV bolus ketamine (0.5 mg/kg) during anesthetic induction,
1919,Randomized Clinical Trial,Xin 2021,[Xin 2021](evidence_tables.html#1919),[Xin 2021](evidence_tables.html#1919),Xin 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"0.5 ug/kg saline 10 minutes before induction, then iv dose of 0.4ug/kg/hr until 30 minutes before the end of surgery",,,,,,
1919,Randomized Clinical Trial,Xin 2021,[Xin 2021](evidence_tables.html#1919),[Xin 2021](evidence_tables.html#1919),Xin 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,"Dexmedetomidine diluted with saline at a concentration of 4ug/mL, as a loading dose 0.5ug/kg dex was administered 10 minutes before anesthesia induction, then as a continuous iv infusion of 0.4ug/kg/hr until 30 minutes before the end of surgery",
1937,Randomized Clinical Trial,Hollinger 2021,[Hollinger 2021](evidence_tables.html#1937),[Hollinger 2021](evidence_tables.html#1937),Hollinger 2021-1,1,Placebo,Control,Placebo,Plac,Ketamine,44,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo,Normal saline (0.9%) once before induction,,,Normal saline (0.9%) once before induction
1937,Randomized Clinical Trial,Hollinger 2021,[Hollinger 2021](evidence_tables.html#1937),[Hollinger 2021](evidence_tables.html#1937),Hollinger 2021-2,2,Haloperidol,Haloperidol,Haloperidol,Hal,Ketamine,45,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Haloperidol,,,,
1937,Randomized Clinical Trial,Hollinger 2021,[Hollinger 2021](evidence_tables.html#1937),[Hollinger 2021](evidence_tables.html#1937),Hollinger 2021-3,3,Ketamine,Ketamine,Ketamine,Ket,Ketamine,47,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,ketamine,1,,,,,,,,,,,,,,,,,Ketamine,,,one dose based on body weight,
2020,Randomized Clinical Trial,Wang 2020b,[Wang 2020b](evidence_tables.html#2020),[Wang 2020b](evidence_tables.html#2020),Wang 2020b-1,1,,,,,Ketamine,13,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2020,Randomized Clinical Trial,Wang 2020b,[Wang 2020b](evidence_tables.html#2020),[Wang 2020b](evidence_tables.html#2020),Wang 2020b-2,2,,,,,Ketamine,12,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2022,Randomized Clinical Trial,Deiner 2017,[Deiner 2017](evidence_tables.html#2022),[Deiner 2017](evidence_tables.html#2022),Deiner 2017-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,201,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 ug/kg/hr of saline placebo at entry to the operation room through 2 hours into revovery
2022,Randomized Clinical Trial,Deiner 2017,[Deiner 2017](evidence_tables.html#2022),[Deiner 2017](evidence_tables.html#2022),Deiner 2017-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,189,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,dexmedetomidine,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,An infusion of dexmedetomidine (0.5 μg/kg/h) or saline placebo was started in patients on entering the operating room and was continued until 2 hours into recovery,
2108,Before-After/Time Series,Braude 2017,[Braude 2017](evidence_tables.html#2108),[Braude 2017](evidence_tables.html#2108),Braude 2017-1,1,,,,,Dexmedetomidine,101,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2108,Before-After/Time Series,Braude 2017,[Braude 2017](evidence_tables.html#2108),[Braude 2017](evidence_tables.html#2108),Braude 2017-2,2,,,,,Dexmedetomidine,124,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2173,Randomized Clinical Trial,Momeni 2021,[Momeni 2021](evidence_tables.html#2173),[Momeni 2021](evidence_tables.html#2173),Momeni 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,203,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Saline infusion from chest closure, for 10 h"
2173,Randomized Clinical Trial,Momeni 2021,[Momeni 2021](evidence_tables.html#2173),[Momeni 2021](evidence_tables.html#2173),Momeni 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,205,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,0.4,,,,,,,,,,,,,,,,,,,,,,,,,"0.4 mcg/kg/h dexmedetomidine infusion from chest closure, for 10 h",
2217,Randomized Clinical Trial,Rascon-Martinez 2016,[Rascon-Martinez 2016](evidence_tables.html#2217),[Rascon-Martinez 2016](evidence_tables.html#2217),Rascon-Martinez 2016-1,1,Placebo,Control,Placebo,Plac,Ketamine,32,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IV administration of physiologic solution after initial sedation and throughout surgery
2217,Randomized Clinical Trial,Rascon-Martinez 2016,[Rascon-Martinez 2016](evidence_tables.html#2217),[Rascon-Martinez 2016](evidence_tables.html#2217),Rascon-Martinez 2016-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,33,kq6_proph_meds,,,,,,,,,,,,,,ketamine,0.3,,,,,,,,,,,,,,,,,,,,IV administration of 0.3 mg/kg ketamine solution after initial sedation and throughout surgery,
2252,Randomized Clinical Trial,Edipoglu 2019,[Edipoglu 2019](evidence_tables.html#2252),[Edipoglu 2019](evidence_tables.html#2252),Edipoglu 2019-1,1,,,,,Ketamine,26,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2252,Randomized Clinical Trial,Edipoglu 2019,[Edipoglu 2019](evidence_tables.html#2252),[Edipoglu 2019](evidence_tables.html#2252),Edipoglu 2019-2,2,,,,,Ketamine,31,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2288,Randomized Clinical Trial,Djainai 2016,[Djainai 2016](evidence_tables.html#2288),[Djainai 2016](evidence_tables.html#2288),Djainai 2016-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,92,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propofol,,Propofol infusion 25 to 50 mcg/kg/min until readiness for tracheal extubation.
2288,Randomized Clinical Trial,Djainai 2016,[Djainai 2016](evidence_tables.html#2288),[Djainai 2016](evidence_tables.html#2288),Djainai 2016-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,91,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,0.4,,0.2,0.7,,,,,,,,,,,,,,,,,,,,,,,"given upon arrival to ICU; received a bolus of 0.4 mcg/kg of dexmedetomidine (over a period of 10-20 min) followed  by an infusion of 0.2 to 0.7 mcg/kg/h. If patient was hemodynamically unstable, the bolus dose was omitted. The infusion was continued for a maximum period of 24h. Dexmedetomidine infusion was not discontinued before extubation.",
2517,Retrospective Cohort,Cheng 2016,[Cheng 2016](evidence_tables.html#2517),[Cheng 2016](evidence_tables.html#2517),Cheng 2016-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,283,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infusion intraoperatively and continued for <24 h postoperatively in ICU
2517,Retrospective Cohort,Cheng 2016,[Cheng 2016](evidence_tables.html#2517),[Cheng 2016](evidence_tables.html#2517),Cheng 2016-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,222,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,dexmedetomidine,,,0.24,0.6,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine administered after cardiopulmonary bypass and continued <24 h postop in ICU,
2578,Randomized Clinical Trial,Lee 2015,[Lee 2015](evidence_tables.html#2578),[Lee 2015](evidence_tables.html#2578),Lee 2015-1,1,Placebo,Control,Placebo,Plac,Ketamine,26,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Administered before induction of anesthesia intravenous bolus, 0.9% normal saline"
2578,Randomized Clinical Trial,Lee 2015,[Lee 2015](evidence_tables.html#2578),[Lee 2015](evidence_tables.html#2578),Lee 2015-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,25,kq6_proph_meds,,,,proph_med_induct,,,,,,,,,,ketamine,0.5,,,,,,,,,,,,,,,,,,,,"single dose of intravenous bolus, a total of 3 mL mixed with 0.9% normal saline and 0.5 mg/kg ketamine",
2598,Randomized Clinical Trial,Wang 2017,[Wang 2017](evidence_tables.html#2598),[Wang 2017](evidence_tables.html#2598),Wang 2017-1,1,Placebo,Control,Placebo,Plac,Ulinastatin,37,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100 mL normal saline and infused intravenously over a period of 20 min before induction. 100 ml daily after surgery on postop days 1 to 3.
2598,Randomized Clinical Trial,Wang 2017,[Wang 2017](evidence_tables.html#2598),[Wang 2017](evidence_tables.html#2598),Wang 2017-2,2,Ulinastatin,Ulinastatin,Ulinastatin,Ulin,Ulinastatin,38,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,,,,,,,ulinastatin,10000,1,,,,,,"10,000 U/kg ulinastatin diluted to 100 mL with normal saline and infused intravenously over a period of 20 min. This was followed by 5000 U/kg ulinastatin daily after surgery on days 1 to 3.",
2624,Randomized Clinical Trial,Subramaniam 2019,[Subramaniam 2019](evidence_tables.html#2624),[Subramaniam 2019](evidence_tables.html#2624),Subramaniam 2019-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,61,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,All preoperative and intraoperative management will be at the discretion of the treating provider and will adhere to the current institutional standard of care for cardiac surgery.,,,,propofol,,20-100 ug/kg/minute postoperatively for sedation
2624,Randomized Clinical Trial,Subramaniam 2019,[Subramaniam 2019](evidence_tables.html#2624),[Subramaniam 2019](evidence_tables.html#2624),Subramaniam 2019-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,59,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,0.5,,0.1,0.4,,,,,,,,,,,,,,,,,,dex group did not receive any propofol during general anesthesia or sedation.,,,,,"IV dexmedetomidine bolus dose of 0.5-1ug/kg during chest closure, followed by a maintenance infusion of 0.1-0.4 ug/kg/hr",
2730,Randomized Clinical Trial,Leung 2017,[Leung 2017](evidence_tables.html#2730),[Leung 2017](evidence_tables.html#2730),Leung 2017-1,1,,,,,Dexmedetomidine,347,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2730,Randomized Clinical Trial,Leung 2017,[Leung 2017](evidence_tables.html#2730),[Leung 2017](evidence_tables.html#2730),Leung 2017-2,2,,,,,Dexmedetomidine,350,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2736,Before-After/Time Series,Ernst 2014,[Ernst 2014](evidence_tables.html#2736),[Ernst 2014](evidence_tables.html#2736),Ernst 2014-1,1,,,,,Dexmedetomidine,160,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2736,Before-After/Time Series,Ernst 2014,[Ernst 2014](evidence_tables.html#2736),[Ernst 2014](evidence_tables.html#2736),Ernst 2014-2,2,,,,,Dexmedetomidine,150,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2748,Randomized Clinical Trial,Lee 2018b,[Lee 2018b](evidence_tables.html#2748),[Lee 2018b](evidence_tables.html#2748),Lee 2018b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,31,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo pregabalin orally 1 hr preop and placebo dexmedetomidine IV during induction and surgery
2748,Randomized Clinical Trial,Lee 2018b,[Lee 2018b](evidence_tables.html#2748),[Lee 2018b](evidence_tables.html#2748),Lee 2018b-2,2,Other,Control,Pregabalin,Preg,Dexmedetomidine,33,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pregabalin,,150 mg pregabalin orally 1 hr preop and placebo dexmedetomidine IV during induction and surgery
2748,Randomized Clinical Trial,Lee 2018b,[Lee 2018b](evidence_tables.html#2748),[Lee 2018b](evidence_tables.html#2748),Lee 2018b-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,31,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.5,,,,,,,,,,,,,,,,,,,,,,,,,placebo pregabalin orally 1 hr preop and 0.5 mg/kg at induction and 0.5 mg/kg/h during surgery dexmedetomidine IV,
2748,Randomized Clinical Trial,Lee 2018b,[Lee 2018b](evidence_tables.html#2748),[Lee 2018b](evidence_tables.html#2748),Lee 2018b-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine/Pregabalin,Dex/Preg,Dexmedetomidine,29,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.5,,,,,,,,,,,,,,,,,,,,,,,,pregabalin,150 mg pregabalin orally 1 hr preop and 0.5 mg/kg at induction and 0.5 mg/kg/h during surgery dexmedetomidine IV,
2778,Randomized Clinical Trial,Glumac 2017,[Glumac 2017](evidence_tables.html#2778),[Glumac 2017](evidence_tables.html#2778),Glumac 2017-1,1,,,,,Dexmedetomidine,81,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2778,Randomized Clinical Trial,Glumac 2017,[Glumac 2017](evidence_tables.html#2778),[Glumac 2017](evidence_tables.html#2778),Glumac 2017-2,2,,,,,Dexmedetomidine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2794,Randomized Clinical Trial,Rohan 2005,[Rohan 2005](evidence_tables.html#2794),[Rohan 2005](evidence_tables.html#2794),Rohan 2005-1,1,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2794,Randomized Clinical Trial,Rohan 2005,[Rohan 2005](evidence_tables.html#2794),[Rohan 2005](evidence_tables.html#2794),Rohan 2005-2,2,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2866,Randomized Clinical Trial,Avidan 2017,[Avidan 2017](evidence_tables.html#2866),[Avidan 2017](evidence_tables.html#2866),Avidan 2017-1,1,Placebo,Control,Placebo,Plac,Ketamine,222,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intravenous normal saline administered following induction of anesthesia but prior to surgical incision
2866,Randomized Clinical Trial,Avidan 2017,[Avidan 2017](evidence_tables.html#2866),[Avidan 2017](evidence_tables.html#2866),Avidan 2017-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,227,kq6_proph_meds,,,,,proph_med_intra,,,,,,,,,ketamine,0.5,,,,,,,,,,,,,,,,,,,,intravenous; administered following induction of anesthesia but prior to surgical incision,
2866,Randomized Clinical Trial,Avidan 2017,[Avidan 2017](evidence_tables.html#2866),[Avidan 2017](evidence_tables.html#2866),Avidan 2017-3,3,Ketamine,Ketamine,Ketamine,Ket,Ketamine,223,kq6_proph_meds,,,,,,,,,,,,,,ketamine,1,,,,,,,,,,,,,,,,,,,,intravenous; administered following induction of anesthesia but prior to surgical incision,
2985,Prospective Cohort,Pipanmekaporn 2021,[Pipanmekaporn 2021](evidence_tables.html#2985),[Pipanmekaporn 2021](evidence_tables.html#2985),Pipanmekaporn 2021-1,1,,,,,Ketamine,173,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2985,Prospective Cohort,Pipanmekaporn 2021,[Pipanmekaporn 2021](evidence_tables.html#2985),[Pipanmekaporn 2021](evidence_tables.html#2985),Pipanmekaporn 2021-2,2,,,,,Ketamine,256,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2997,Before-After/Time Series,Miyata 2017,[Miyata 2017](evidence_tables.html#2997),[Miyata 2017](evidence_tables.html#2997),Miyata 2017-1,1,None,Control,None,None,Ramelteon,58,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2997,Before-After/Time Series,Miyata 2017,[Miyata 2017](evidence_tables.html#2997),[Miyata 2017](evidence_tables.html#2997),Miyata 2017-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,24,kq6_proph_meds,,,,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,8,7,,,,,,,,,,,,,
3046,Randomized Clinical Trial,Hu 2021,[Hu 2021](evidence_tables.html#3046),[Hu 2021](evidence_tables.html#3046),Hu 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,87,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9% saline IV during induction and throughout surgery
3046,Randomized Clinical Trial,Hu 2021,[Hu 2021](evidence_tables.html#3046),[Hu 2021](evidence_tables.html#3046),Hu 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,90,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.4,0.1,,,,,,,,,,,,,,,,,,,,,,,,,0.4 mg/kg loading dose and 0.1 mg/kg/h maintenance dexmedetomidine IV during induction and throughout surgery,
3130,Randomized Clinical Trial,Lu 2017,[Lu 2017](evidence_tables.html#3130),[Lu 2017](evidence_tables.html#3130),Lu 2017-1,1,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,76,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.5,,,,,,,,,,,,,,,,,,,,,,,,,"15 min before induction, parecoxib sodium plus dexmedetomidine (loading 0.5 mcg/kg and 0.5 mcg/kg/h maintenance) through surgery, followed by sufentanil (0.04 mcg/kg/h) postsurgery",
3130,Randomized Clinical Trial,Lu 2017,[Lu 2017](evidence_tables.html#3130),[Lu 2017](evidence_tables.html#3130),Lu 2017-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,75,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,proph_med_postop,,dexmedetomidine,0.5,0.5,,,0.06,,,,,,,,,,,,,,,,,,,,,,"15 min before induction, parecoxib sodium plus dexmedetomidine (loading 0.5 mcg/kg and 0.5 mcg/kg/h maintenance) through surgery, followed by sufentanil (0.04 mcg/kg/h) plus dexmedetomidine (0.06 mcg/kg/h) postsurgery",
3218,Randomized Clinical Trial,Alas 2020,[Alas 2020](evidence_tables.html#3218),[Alas 2020](evidence_tables.html#3218),Alas 2020-1,1,,,,,Dexmedetomidine,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3218,Randomized Clinical Trial,Alas 2020,[Alas 2020](evidence_tables.html#3218),[Alas 2020](evidence_tables.html#3218),Alas 2020-2,2,,,,,Dexmedetomidine,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3250,Randomized Clinical Trial,Royse 2017,[Royse 2017](evidence_tables.html#3250),[Royse 2017](evidence_tables.html#3250) ([Whitlock 2015](evidence_tables.html#10515)),Royse 2017-1,1,,,,,Dexmedetomidine,246,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3250,Randomized Clinical Trial,Royse 2017,[Royse 2017](evidence_tables.html#3250),[Royse 2017](evidence_tables.html#3250) ([Whitlock 2015](evidence_tables.html#10515)),Royse 2017-2,2,,,,,Dexmedetomidine,236,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3391,Randomized Clinical Trial,Shi 2020,[Shi 2020](evidence_tables.html#3391),[Shi 2020](evidence_tables.html#3391),Shi 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,53,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 ug/kg/h saline intravenously
3391,Randomized Clinical Trial,Shi 2020,[Shi 2020](evidence_tables.html#3391),[Shi 2020](evidence_tables.html#3391),Shi 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,53,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,0.5 ug/kg/h dexmedetomidine intravenously from induction to chest closure,
3716,Randomized Clinical Trial,Zhao 2020,[Zhao 2020](evidence_tables.html#3716),[Zhao 2020](evidence_tables.html#3716),Zhao 2020-1,1,None,Control,None,None,Dexmedetomidine,101,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dex 0 mcg group (0 mcg dex + 150 mcg sufentanil + 300 ml of 0.9% saline in the PCA pump. Intraoperative
3716,Randomized Clinical Trial,Zhao 2020,[Zhao 2020](evidence_tables.html#3716),[Zhao 2020](evidence_tables.html#3716),Zhao 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,108,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,100,,,,,,,,,,,,,,,,,,,,,,,,,Dex 100 mcg group (100 mcg dex + 150 mcg sufentanil + 300 ml of 0.9% saline in the PCA pump; loading dose given over 10 min,
3716,Randomized Clinical Trial,Zhao 2020,[Zhao 2020](evidence_tables.html#3716),[Zhao 2020](evidence_tables.html#3716),Zhao 2020-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,105,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,200,,,,,,,,,,,,,,,,,,,,,,,,,Dex 200 mcg group (200 mcg dex + 150 mcg sufentanil + 300 ml of 0.9% saline in the PCA pump; loading dose given over 10 min,
3716,Randomized Clinical Trial,Zhao 2020,[Zhao 2020](evidence_tables.html#3716),[Zhao 2020](evidence_tables.html#3716),Zhao 2020-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,102,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,400,,,,,,,,,,,,,,,,,,,,,,,,,Dex 400 mcg group (400 mcg dex + 150 mcg sufentanil + 300 ml of 0.9% saline in the PCA pump; loading dose given over 10 min,
3727,Retrospective Cohort,Mangusan 2015a,[Mangusan 2015a](evidence_tables.html#3727),[Mangusan 2015a](evidence_tables.html#3727),Mangusan 2015a-1,1,,,,,Dexmedetomidine,424,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3727,Retrospective Cohort,Mangusan 2015a,[Mangusan 2015a](evidence_tables.html#3727),[Mangusan 2015a](evidence_tables.html#3727),Mangusan 2015a-2,2,,,,,Dexmedetomidine,232,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3788,Randomized Clinical Trial,Remerand 2009,[Remerand 2009](evidence_tables.html#3788),[Remerand 2009](evidence_tables.html#3788),Remerand 2009-1,1,Placebo,Control,Placebo,Plac,Ketamine,75,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3788,Randomized Clinical Trial,Remerand 2009,[Remerand 2009](evidence_tables.html#3788),[Remerand 2009](evidence_tables.html#3788),Remerand 2009-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,79,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,,,,,,,ketamine,0.5,,2,,,,,,,,,,,,,,,,,,1 bolus during surgery followed by 24-h infusion using the second study syringe at 2 mL/h (equivalent to 2 ug/kg/min).,
3841,Randomized Clinical Trial,Oh 2021,[Oh 2021](evidence_tables.html#3841),[Oh 2021](evidence_tables.html#3841),Oh 2021-1,1,Placebo,Control,Placebo,Plac,Ramelteon,39,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Capsule shells filled with microcrystalline cellulose Riboflavin 100mg (adherence marker); 1 pre-operative and 2 nightly postoperative doses
3841,Randomized Clinical Trial,Oh 2021,[Oh 2021](evidence_tables.html#3841),[Oh 2021](evidence_tables.html#3841),Oh 2021-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,41,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,8,3,,,,,,,,,,,,Ramelteon 8 mg oral dose with Riboflavin 100 (adherence marker); 1 pre-operative and 2 nightly postoperative doses,
4033,Randomized Clinical Trial,Qiao 2015,[Qiao 2015](evidence_tables.html#4033),[Qiao 2015](evidence_tables.html#4033),Qiao 2015-1,1,,,,,Ramelteon,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4033,Randomized Clinical Trial,Qiao 2015,[Qiao 2015](evidence_tables.html#4033),[Qiao 2015](evidence_tables.html#4033),Qiao 2015-2,2,,,,,Ramelteon,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4150,Randomized Clinical Trial,Jaiswal 2019,[Jaiswal 2019](evidence_tables.html#4150),[Jaiswal 2019](evidence_tables.html#4150),Jaiswal 2019-1,1,Placebo,Control,Placebo,Plac,Ramelteon,58,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Placebo, administered 1 day prior to surgery, maximum 7 days"
4150,Randomized Clinical Trial,Jaiswal 2019,[Jaiswal 2019](evidence_tables.html#4150),[Jaiswal 2019](evidence_tables.html#4150),Jaiswal 2019-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,59,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,8,6,,,,,,,,,,,,"ramelteon 8 mg, administered 1 day prior to surgery, maximum 7 days",
4782,Randomized Clinical Trial,Liang 2017,[Liang 2017](evidence_tables.html#4782),[Liang 2017](evidence_tables.html#4782),Liang 2017-1,1,,,,,Ramelteon,66,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4782,Randomized Clinical Trial,Liang 2017,[Liang 2017](evidence_tables.html#4782),[Liang 2017](evidence_tables.html#4782),Liang 2017-2,2,,,,,Ramelteon,66,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4782,Randomized Clinical Trial,Liang 2017,[Liang 2017](evidence_tables.html#4782),[Liang 2017](evidence_tables.html#4782),Liang 2017-3,3,,,,,Ramelteon,66,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4798,Randomized Clinical Trial,Ding 2015,[Ding 2015](evidence_tables.html#4798),[Ding 2015](evidence_tables.html#4798),Ding 2015-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,20,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline in 50 mL injector
4798,Randomized Clinical Trial,Ding 2015,[Ding 2015](evidence_tables.html#4798),[Ding 2015](evidence_tables.html#4798),Ding 2015-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,20,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,2,,,,,,,,,,,,,,,,,,,,,,,,,,2 mg diluted in 50 ml solution,
4824,Randomized Clinical Trial,Hakim 2012,[Hakim 2012](evidence_tables.html#4824),[Hakim 2012](evidence_tables.html#4824),Hakim 2012-1,1,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4824,Randomized Clinical Trial,Hakim 2012,[Hakim 2012](evidence_tables.html#4824),[Hakim 2012](evidence_tables.html#4824),Hakim 2012-2,2,,,,,Dexmedetomidine,51,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4888,Retrospective Cohort,Weinstein 2018a,[Weinstein 2018a](evidence_tables.html#4888),[Weinstein 2018a](evidence_tables.html#4888),Weinstein 2018a-1,1,,,,,Dexmedetomidine,2643,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4888,Retrospective Cohort,Weinstein 2018a,[Weinstein 2018a](evidence_tables.html#4888),[Weinstein 2018a](evidence_tables.html#4888),Weinstein 2018a-2,2,,,,,Dexmedetomidine,33223,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4914,Randomized Clinical Trial,Li 2021b,[Li 2021b](evidence_tables.html#4914),[Li 2021b](evidence_tables.html#4914),Li 2021b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline infusion
4914,Randomized Clinical Trial,Li 2021b,[Li 2021b](evidence_tables.html#4914),[Li 2021b](evidence_tables.html#4914),Li 2021b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.3,0.2,,,,,,,,,,,,,,,,,,,,,,,,,small-dose,
4914,Randomized Clinical Trial,Li 2021b,[Li 2021b](evidence_tables.html#4914),[Li 2021b](evidence_tables.html#4914),Li 2021b-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.3,0.5,,,,,,,,,,,,,,,,,,,,,,,,,medium-dose,
4914,Randomized Clinical Trial,Li 2021b,[Li 2021b](evidence_tables.html#4914),[Li 2021b](evidence_tables.html#4914),Li 2021b-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.3,0.8,,,,,,,,,,,,,,,,,,,,,,,,,high-dose,
5024,Randomized Clinical Trial,Li 2015,[Li 2015](evidence_tables.html#5024),[Li 2015](evidence_tables.html#5024),Li 2015-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline infusion
5024,Randomized Clinical Trial,Li 2015,[Li 2015](evidence_tables.html#5024),[Li 2015](evidence_tables.html#5024),Li 2015-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,50,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.4,,,,,,,,,,,,,,,,,,,,,,,,,loading dose 1 mg/kg over 10 min,
5052,Nonrandomized Trial,Zhang 2019b,[Zhang 2019b](evidence_tables.html#5052),[Zhang 2019b](evidence_tables.html#5052),Zhang 2019b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,60,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infusion intraoperatively
5052,Nonrandomized Trial,Zhang 2019b,[Zhang 2019b](evidence_tables.html#5052),[Zhang 2019b](evidence_tables.html#5052),Zhang 2019b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,80,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,1,,0.2,0.7,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine initiated after intubation and maintained up to 30 minutes before end of surgery,
5066,Retrospective Cohort,Park 2021,[Park 2021](evidence_tables.html#5066),[Park 2021](evidence_tables.html#5066),Park 2021-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,357,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propofol,,
5066,Retrospective Cohort,Park 2021,[Park 2021](evidence_tables.html#5066),[Park 2021](evidence_tables.html#5066),Park 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,357,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,,0.1,0.5,,,,,,,,,,,,,,,,,,,,,,,,
5147,Randomized Clinical Trial,Zhang 2020a,[Zhang 2020a](evidence_tables.html#5147),[Zhang 2020a](evidence_tables.html#5147),Zhang 2020a-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,120,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"If spinal anesthesia failed then CSE was administered, if CSE failed then general anesthesia was administered.",,,,,,Normal saline infused 30 min before anesthesia and discontinued 30 min before surgery
5147,Randomized Clinical Trial,Zhang 2020a,[Zhang 2020a](evidence_tables.html#5147),[Zhang 2020a](evidence_tables.html#5147),Zhang 2020a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,120,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.5,0.3,,,,,,,,,,,,,,,,,,,,,,,,,drug infused 30 min before anesthesia and discontinued 30 min before end of surgery,
5163,Retrospective Cohort,Memtsoudis 2019a,[Memtsoudis 2019a](evidence_tables.html#5163),[Memtsoudis 2019a](evidence_tables.html#5163),Memtsoudis 2019a-1,1,,,,,Dexmedetomidine,107736,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5163,Retrospective Cohort,Memtsoudis 2019a,[Memtsoudis 2019a](evidence_tables.html#5163),[Memtsoudis 2019a](evidence_tables.html#5163),Memtsoudis 2019a-2,2,,,,,Dexmedetomidine,373219,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5163,Retrospective Cohort,Memtsoudis 2019a,[Memtsoudis 2019a](evidence_tables.html#5163),[Memtsoudis 2019a](evidence_tables.html#5163),Memtsoudis 2019a-3,3,,,,,Dexmedetomidine,15329,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5163,Retrospective Cohort,Memtsoudis 2019a,[Memtsoudis 2019a](evidence_tables.html#5163),[Memtsoudis 2019a](evidence_tables.html#5163),Memtsoudis 2019a-4,4,,,,,Dexmedetomidine,67942,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5164,Randomized Clinical Trial,Sultan 2010,[Sultan 2010](evidence_tables.html#5164),[Sultan 2010](evidence_tables.html#5164),Sultan 2010-1,1,None,Control,None,None,Melatonin,49,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,None,,,,
5164,Randomized Clinical Trial,Sultan 2010,[Sultan 2010](evidence_tables.html#5164),[Sultan 2010](evidence_tables.html#5164),Sultan 2010-2,2,Midazolam,Midazolam,Midazolam,Mid,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"compares melatonin to midazolam, clonidine, and control",Midazolam,,,,
5164,Randomized Clinical Trial,Sultan 2010,[Sultan 2010](evidence_tables.html#5164),[Sultan 2010](evidence_tables.html#5164),Sultan 2010-3,3,Melatonin,Melatonin,Melatonin,Mel,Melatonin,53,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,,,,,melatonin,5,2,,,,,,,,,,,,Melatonin,,,one dose night before and another 90 min before surgery,
5183,Nonrandomized Trial,Xu 2017,[Xu 2017](evidence_tables.html#5183),[Xu 2017](evidence_tables.html#5183),Xu 2017-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,48,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline in same volume was given
5183,Nonrandomized Trial,Xu 2017,[Xu 2017](evidence_tables.html#5183),[Xu 2017](evidence_tables.html#5183),Xu 2017-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,48,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine was pumped at a rate of 0.5 μg/(kg h),
5189,Randomized Clinical Trial,Siripoonyothai 2021,[Siripoonyothai 2021](evidence_tables.html#5189),[Siripoonyothai 2021](evidence_tables.html#5189),Siripoonyothai 2021-1,1,Other,Control,Propofol,Prop,Ketamine,32,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propofol,,Propofol infusion 1.5-6 mg/kg/h intraop
5189,Randomized Clinical Trial,Siripoonyothai 2021,[Siripoonyothai 2021](evidence_tables.html#5189),[Siripoonyothai 2021](evidence_tables.html#5189),Siripoonyothai 2021-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,32,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,,,,,,,ketamine,,1,,,,,,,,,,,,,,,,,,,infusion at 1 mg/kg/h,
5240,Randomized Clinical Trial,Hong 2021,[Hong 2021](evidence_tables.html#5240),[Hong 2021](evidence_tables.html#5240),Hong 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,354,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"procedure was performed under neuraxial anesthesia or a peripheral nerve block, either combined with general anesthesia. Neuraxial anesthesia included epidural and combined spinal-epidural anesthesia. Peripheral nerve blocks included lumbar plexus, sciatic nerve, femoral nerve, and iliac fascial space.",,,,,,0.9% saline + 200 ug sufentanil via PCIVA as 2 ml boluses postoperatively
5240,Randomized Clinical Trial,Hong 2021,[Hong 2021](evidence_tables.html#5240),[Hong 2021](evidence_tables.html#5240),Hong 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,356,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,,,0.026,,,,,,,,,,,,,,,,,,,,,,200 ug dex + 200 ug sufentanil via PCIVA as 2 ml boluses postoperatively,
5251,Randomized Clinical Trial,Chawdhary 2020,[Chawdhary 2020](evidence_tables.html#5251),[Chawdhary 2020](evidence_tables.html#5251),Chawdhary 2020-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,40,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Both groups got 2 mg/kg of Propofol at induction,,,,propofol,,Intravenous (IV) infusion of propofol 80–100 μg/kg/min
5251,Randomized Clinical Trial,Chawdhary 2020,[Chawdhary 2020](evidence_tables.html#5251),[Chawdhary 2020](evidence_tables.html#5251),Chawdhary 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,40,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,0.5,0.7,,,,,,,,,,,,,,,,,,,,,,,,
5269,Randomized Clinical Trial,Gao 2021,[Gao 2021](evidence_tables.html#5269),[Gao 2021](evidence_tables.html#5269) ([Gao 2020](evidence_tables.html#1819)),Gao 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,20,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline 0.9% 15 min before induction and continuous pump injection until end of surgery
5269,Randomized Clinical Trial,Gao 2021,[Gao 2021](evidence_tables.html#5269),[Gao 2021](evidence_tables.html#5269) ([Gao 2020](evidence_tables.html#1819)),Gao 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,20,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.6,0.2,,,,,,,,,,,,,,,,,,,,,,,,,15 min before induction and continuous pump injection until end of surgery,
5365,Crossover Trial,Spence 2020,[Spence 2020](evidence_tables.html#5365),[Spence 2020](evidence_tables.html#5365),Spence 2020-1,1,,,,,Dexmedetomidine,411,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5365,Crossover Trial,Spence 2020,[Spence 2020](evidence_tables.html#5365),[Spence 2020](evidence_tables.html#5365),Spence 2020-2,2,,,,,Dexmedetomidine,389,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5436,Randomized Clinical Trial,Chen 2013,[Chen 2013](evidence_tables.html#5436),[Chen 2013](evidence_tables.html#5436),Chen 2013-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,63,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo infusion of normal saline
5436,Randomized Clinical Trial,Chen 2013,[Chen 2013](evidence_tables.html#5436),[Chen 2013](evidence_tables.html#5436),Chen 2013-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,59,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.4,,,,,,,,,,,,,,,,,,,,,,,,,continuous infusion 4 mg/kg/h until end of surgery,
5452,Randomized Clinical Trial,Guo 2015,[Guo 2015](evidence_tables.html#5452),[Guo 2015](evidence_tables.html#5452),Guo 2015-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,73,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infusion for 12 hours upon admission to SICU
5452,Randomized Clinical Trial,Guo 2015,[Guo 2015](evidence_tables.html#5452),[Guo 2015](evidence_tables.html#5452),Guo 2015-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,76,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,,,0.2,,,,,,,,,,,,,,,,,,,,,,administered for 12 hours after SICU admission,
5480,Randomized Clinical Trial,Zhang 2021,[Zhang 2021](evidence_tables.html#5480),[Zhang 2021](evidence_tables.html#5480),Zhang 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,87,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Saline administered for 10 min, intraoperatively"
5480,Randomized Clinical Trial,Zhang 2021,[Zhang 2021](evidence_tables.html#5480),[Zhang 2021](evidence_tables.html#5480),Zhang 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,87,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,
5765,Randomized Clinical Trial,Zhu 2018,[Zhu 2018](evidence_tables.html#5765),[Zhu 2018](evidence_tables.html#5765),Zhu 2018-1,1,,,,,Dexmedetomidine,82,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5765,Randomized Clinical Trial,Zhu 2018,[Zhu 2018](evidence_tables.html#5765),[Zhu 2018](evidence_tables.html#5765),Zhu 2018-2,2,,,,,Dexmedetomidine,81,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5809,Randomized Clinical Trial,Zhou 2019a,[Zhou 2019a](evidence_tables.html#5809),[Zhou 2019a](evidence_tables.html#5809),Zhou 2019a-1,1,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5809,Randomized Clinical Trial,Zhou 2019a,[Zhou 2019a](evidence_tables.html#5809),[Zhou 2019a](evidence_tables.html#5809),Zhou 2019a-2,2,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5809,Randomized Clinical Trial,Zhou 2019a,[Zhou 2019a](evidence_tables.html#5809),[Zhou 2019a](evidence_tables.html#5809),Zhou 2019a-3,3,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5894,Randomized Clinical Trial,Mandal 2011,[Mandal 2011](evidence_tables.html#5894),[Mandal 2011](evidence_tables.html#5894),Mandal 2011-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5894,Randomized Clinical Trial,Mandal 2011,[Mandal 2011](evidence_tables.html#5894),[Mandal 2011](evidence_tables.html#5894),Mandal 2011-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5915,Randomized Clinical Trial,Jellish 2003,[Jellish 2003](evidence_tables.html#5915),[Jellish 2003](evidence_tables.html#5915),Jellish 2003-1,1,,,,,Dexmedetomidine,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5915,Randomized Clinical Trial,Jellish 2003,[Jellish 2003](evidence_tables.html#5915),[Jellish 2003](evidence_tables.html#5915),Jellish 2003-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6017,Before-After/Time Series,Souwer 2018,[Souwer 2018](evidence_tables.html#6017),[Souwer 2018](evidence_tables.html#6017),Souwer 2018-1,1,,,,,Dexmedetomidine,63,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6017,Before-After/Time Series,Souwer 2018,[Souwer 2018](evidence_tables.html#6017),[Souwer 2018](evidence_tables.html#6017),Souwer 2018-2,2,,,,,Dexmedetomidine,86,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6072,Randomized Clinical Trial,Meuret 2018,[Meuret 2018](evidence_tables.html#6072),[Meuret 2018](evidence_tables.html#6072),Meuret 2018-1,1,,,,,Dexmedetomidine,21,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6072,Randomized Clinical Trial,Meuret 2018,[Meuret 2018](evidence_tables.html#6072),[Meuret 2018](evidence_tables.html#6072),Meuret 2018-2,2,,,,,Dexmedetomidine,19,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6109,Randomized Clinical Trial,Shin 2020,[Shin 2020](evidence_tables.html#6109),[Shin 2020](evidence_tables.html#6109),Shin 2020-1,1,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhaled,,,,,
6109,Randomized Clinical Trial,Shin 2020,[Shin 2020](evidence_tables.html#6109),[Shin 2020](evidence_tables.html#6109),Shin 2020-2,2,,,,,Dexmedetomidine,58,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TIVA,,,,,
6109,Randomized Clinical Trial,Shin 2020,[Shin 2020](evidence_tables.html#6109),[Shin 2020](evidence_tables.html#6109),Shin 2020-3,3,,,,,Dexmedetomidine,58,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6132,Randomized Clinical Trial,Wang 2016,[Wang 2016](evidence_tables.html#6132),[Wang 2016](evidence_tables.html#6132),Wang 2016-1,1,,,,,Dexmedetomidine,103,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6132,Randomized Clinical Trial,Wang 2016,[Wang 2016](evidence_tables.html#6132),[Wang 2016](evidence_tables.html#6132),Wang 2016-2,2,,,,,Dexmedetomidine,103,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6506,Randomized Clinical Trial,Dai 2021,[Dai 2021](evidence_tables.html#6506),[Dai 2021](evidence_tables.html#6506),Dai 2021-1,1,,,,,Dexmedetomidine,81,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6506,Randomized Clinical Trial,Dai 2021,[Dai 2021](evidence_tables.html#6506),[Dai 2021](evidence_tables.html#6506),Dai 2021-2,2,,,,,Dexmedetomidine,83,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6540,Randomized Clinical Trial,Bielka 2021,[Bielka 2021](evidence_tables.html#6540),[Bielka 2021](evidence_tables.html#6540),Bielka 2021-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6540,Randomized Clinical Trial,Bielka 2021,[Bielka 2021](evidence_tables.html#6540),[Bielka 2021](evidence_tables.html#6540),Bielka 2021-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6540,Randomized Clinical Trial,Bielka 2021,[Bielka 2021](evidence_tables.html#6540),[Bielka 2021](evidence_tables.html#6540),Bielka 2021-3,3,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6840,Prospective Cohort,Ke 2022a,[Ke 2022a](evidence_tables.html#6840),[Ke 2022a](evidence_tables.html#6840),Ke 2022a-1,1,,,,,Dexmedetomidine,91,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6840,Prospective Cohort,Ke 2022a,[Ke 2022a](evidence_tables.html#6840),[Ke 2022a](evidence_tables.html#6840),Ke 2022a-2,2,,,,,Dexmedetomidine,7,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6964,Retrospective Cohort,Cho 2021,[Cho 2021](evidence_tables.html#6964),[Cho 2021](evidence_tables.html#6964),Cho 2021-1,1,,,,,Dexmedetomidine,1202,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6964,Retrospective Cohort,Cho 2021,[Cho 2021](evidence_tables.html#6964),[Cho 2021](evidence_tables.html#6964),Cho 2021-2,2,,,,,Dexmedetomidine,1374,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7098,Randomized Clinical Trial,Larsen 2010,[Larsen 2010](evidence_tables.html#7098),[Larsen 2010](evidence_tables.html#7098),Larsen 2010-1,1,,,,,Dexmedetomidine,204,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7098,Randomized Clinical Trial,Larsen 2010,[Larsen 2010](evidence_tables.html#7098),[Larsen 2010](evidence_tables.html#7098),Larsen 2010-2,2,,,,,Dexmedetomidine,196,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7151,Randomized Clinical Trial,Wang 2022a,[Wang 2022a](evidence_tables.html#7151),[Wang 2022a](evidence_tables.html#7151),Wang 2022a-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,60,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline infusion
7151,Randomized Clinical Trial,Wang 2022a,[Wang 2022a](evidence_tables.html#7151),[Wang 2022a](evidence_tables.html#7151),Wang 2022a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,60,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,
7240,Randomized Clinical Trial,Chitnis 2022,[Chitnis 2022](evidence_tables.html#7240),[Chitnis 2022](evidence_tables.html#7240),Chitnis 2022-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,33,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propofol,,Propofol received an IV maintenance infusion of 10% propofol at 25 to 50 mcg/kg/min postoperatively until normothermic and hemodynamically stable
7240,Randomized Clinical Trial,Chitnis 2022,[Chitnis 2022](evidence_tables.html#7240),[Chitnis 2022](evidence_tables.html#7240),Chitnis 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,34,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,0.5,0,1.5,,,,,,,,,,,,,,,,,,,,,,,Iv maintenance infusion starting at 0.5 mcg/kg/h and was titrated as required from 0 to 1.5 mcg/kg/h postoperatively until normothermic and hemodynamically stable,
7309,Randomized Clinical Trial,Fukata 2017,[Fukata 2017](evidence_tables.html#7309),[Fukata 2017](evidence_tables.html#7309),Fukata 2017-1,1,,,,,Dexmedetomidine,100,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7309,Randomized Clinical Trial,Fukata 2017,[Fukata 2017](evidence_tables.html#7309),[Fukata 2017](evidence_tables.html#7309),Fukata 2017-2,2,,,,,Dexmedetomidine,101,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7490,Randomized Clinical Trial,Li 2022,[Li 2022](evidence_tables.html#7490),[Li 2022](evidence_tables.html#7490),Li 2022-1,1,,,,,Dexmedetomidine,471,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7490,Randomized Clinical Trial,Li 2022,[Li 2022](evidence_tables.html#7490),[Li 2022](evidence_tables.html#7490),Li 2022-2,2,,,,,Dexmedetomidine,471,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7522,Prospective Cohort,Leigheb 2022,[Leigheb 2022](evidence_tables.html#7522),[Leigheb 2022](evidence_tables.html#7522),Leigheb 2022-1,1,,,,,Dexmedetomidine,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7522,Prospective Cohort,Leigheb 2022,[Leigheb 2022](evidence_tables.html#7522),[Leigheb 2022](evidence_tables.html#7522),Leigheb 2022-2,2,,,,,Dexmedetomidine,47,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7554,Randomized Clinical Trial,Brown 2021,[Brown 2021](evidence_tables.html#7554),[Brown 2021](evidence_tables.html#7554),Brown 2021-1,1,,,,,Dexmedetomidine,106,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7554,Randomized Clinical Trial,Brown 2021,[Brown 2021](evidence_tables.html#7554),[Brown 2021](evidence_tables.html#7554),Brown 2021-2,2,,,,,Dexmedetomidine,111,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7686,Randomized Clinical Trial,Xiang 2022,[Xiang 2022](evidence_tables.html#7686),[Xiang 2022](evidence_tables.html#7686),Xiang 2022-1,1,,,,,Dexmedetomidine,84,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7686,Randomized Clinical Trial,Xiang 2022,[Xiang 2022](evidence_tables.html#7686),[Xiang 2022](evidence_tables.html#7686),Xiang 2022-2,2,,,,,Dexmedetomidine,84,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-1,1,,,,,Dexmedetomidine,560,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-2,2,,,,,Dexmedetomidine,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-3,3,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-4,4,,,,,Dexmedetomidine,339,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-5,5,,,,,Dexmedetomidine,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
7722,Prospective Cohort,Duprey 2022,[Duprey 2022](evidence_tables.html#7722),[Duprey 2022](evidence_tables.html#7722),Duprey 2022-6,6,,,,,Dexmedetomidine,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8003,Retrospective Cohort,Fuchita 2019a,[Fuchita 2019a](evidence_tables.html#8003),[Fuchita 2019a](evidence_tables.html#8003),Fuchita 2019a-1,1,,,,,Dexmedetomidine,3,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8003,Retrospective Cohort,Fuchita 2019a,[Fuchita 2019a](evidence_tables.html#8003),[Fuchita 2019a](evidence_tables.html#8003),Fuchita 2019a-2,2,,,,,Dexmedetomidine,81,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8117,Randomized Clinical Trial,Neuman 2021,[Neuman 2021](evidence_tables.html#8117),[Neuman 2021](evidence_tables.html#8117),Neuman 2021-1,1,,,,,Dexmedetomidine,804,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8117,Randomized Clinical Trial,Neuman 2021,[Neuman 2021](evidence_tables.html#8117),[Neuman 2021](evidence_tables.html#8117),Neuman 2021-2,2,,,,,Dexmedetomidine,795,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8558,Randomized Clinical Trial,Lu 2021,[Lu 2021](evidence_tables.html#8558),[Lu 2021](evidence_tables.html#8558),Lu 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,331,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infused 0.5 ug/kg for 15 minutes followed by 0.2 ug/kg/hr through a continuous pump until 30 minutes before the end of sugery
8558,Randomized Clinical Trial,Lu 2021,[Lu 2021](evidence_tables.html#8558),[Lu 2021](evidence_tables.html#8558),Lu 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,344,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.2,,,,,,,,,,,,,,,,,,,,,,,,,dexemeditomidine infused 0.5 ug/kg for 15 minutes followed by 0.2 ug/kg/hr through a continuous pump until 30 minutes before the end of sugery,
8574,Randomized Clinical Trial,Kalisvaart 2005,[Kalisvaart 2005](evidence_tables.html#8574),[Kalisvaart 2005](evidence_tables.html#8574),Kalisvaart 2005-1,1,,,,,Dexmedetomidine,218,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8574,Randomized Clinical Trial,Kalisvaart 2005,[Kalisvaart 2005](evidence_tables.html#8574),[Kalisvaart 2005](evidence_tables.html#8574),Kalisvaart 2005-2,2,,,,,Dexmedetomidine,212,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8864,Randomized Clinical Trial,Fukata 2014,[Fukata 2014](evidence_tables.html#8864),[Fukata 2014](evidence_tables.html#8864),Fukata 2014-1,1,,,,,Dexmedetomidine,62,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8864,Randomized Clinical Trial,Fukata 2014,[Fukata 2014](evidence_tables.html#8864),[Fukata 2014](evidence_tables.html#8864),Fukata 2014-2,2,,,,,Dexmedetomidine,59,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9011,Randomized Clinical Trial,Ding 2021,[Ding 2021](evidence_tables.html#9011),[Ding 2021](evidence_tables.html#9011),Ding 2021-1,1,,,,,Dexmedetomidine,90,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9011,Randomized Clinical Trial,Ding 2021,[Ding 2021](evidence_tables.html#9011),[Ding 2021](evidence_tables.html#9011),Ding 2021-2,2,,,,,Dexmedetomidine,90,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9157,Randomized Clinical Trial,Tan 2022,[Tan 2022](evidence_tables.html#9157),[Tan 2022](evidence_tables.html#9157),Tan 2022-1,1,,,,,Dexmedetomidine,33,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9157,Randomized Clinical Trial,Tan 2022,[Tan 2022](evidence_tables.html#9157),[Tan 2022](evidence_tables.html#9157),Tan 2022-2,2,,,,,Dexmedetomidine,33,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9157,Randomized Clinical Trial,Tan 2022,[Tan 2022](evidence_tables.html#9157),[Tan 2022](evidence_tables.html#9157),Tan 2022-3,3,,,,,Dexmedetomidine,33,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9196,Randomized Clinical Trial,Wang 2012,[Wang 2012](evidence_tables.html#9196),[Wang 2012](evidence_tables.html#9196),Wang 2012-1,1,,,,,Dexmedetomidine,228,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9196,Randomized Clinical Trial,Wang 2012,[Wang 2012](evidence_tables.html#9196),[Wang 2012](evidence_tables.html#9196),Wang 2012-2,2,,,,,Dexmedetomidine,229,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9256,Randomized Clinical Trial,Javaherforoosh 2021,[Javaherforoosh 2021](evidence_tables.html#9256),[Javaherforoosh 2021](evidence_tables.html#9256),Javaherforoosh 2021-1,1,Placebo,Control,Placebo,Plac,Melatonin,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3mg capsules of cornstarch the evening before the operation and the morning of surgery, continuing until the second postop day"
9256,Randomized Clinical Trial,Javaherforoosh 2021,[Javaherforoosh 2021](evidence_tables.html#9256),[Javaherforoosh 2021](evidence_tables.html#9256),Javaherforoosh 2021-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,30,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,3,3,,,,,,,,,,,,,,,"3mg of melatonin (prolonged-release tablets; webber naturals, canada) the evening before surgery, 3mg the morning of surgery, and continued until postop day 2",
9279,Case-Control,Nandi 2014,[Nandi 2014](evidence_tables.html#9279),[Nandi 2014](evidence_tables.html#9279),Nandi 2014-1,1,,,,,Melatonin,376,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9279,Case-Control,Nandi 2014,[Nandi 2014](evidence_tables.html#9279),[Nandi 2014](evidence_tables.html#9279),Nandi 2014-2,2,,,,,Melatonin,87,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9464,Before-After/Time Series,Ushida 2009,[Ushida 2009](evidence_tables.html#9464),[Ushida 2009](evidence_tables.html#9464),Ushida 2009-1,1,,,,,Melatonin,41,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9464,Before-After/Time Series,Ushida 2009,[Ushida 2009](evidence_tables.html#9464),[Ushida 2009](evidence_tables.html#9464),Ushida 2009-2,2,,,,,Melatonin,81,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9616,Prospective Cohort,Barreto Chang 2022,[Barreto Chang 2022](evidence_tables.html#9616),[Barreto Chang 2022](evidence_tables.html#9616),Barreto Chang 2022-1,1,None,Control,None,None,Ketamine,38,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9616,Prospective Cohort,Barreto Chang 2022,[Barreto Chang 2022](evidence_tables.html#9616),[Barreto Chang 2022](evidence_tables.html#9616),Barreto Chang 2022-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,60,kq6_proph_meds,,,,,,,proph_med_unspec,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,no details given,
9620,Randomized Clinical Trial,Aizawa 2002,[Aizawa 2002](evidence_tables.html#9620),[Aizawa 2002](evidence_tables.html#9620),Aizawa 2002-1,1,,,,,Ketamine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9620,Randomized Clinical Trial,Aizawa 2002,[Aizawa 2002](evidence_tables.html#9620),[Aizawa 2002](evidence_tables.html#9620),Aizawa 2002-2,2,,,,,Ketamine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9741,Randomized Clinical Trial,Shi 2021,[Shi 2021](evidence_tables.html#9741),[Shi 2021](evidence_tables.html#9741),Shi 2021-1,1,Placebo,Control,Placebo,Plac,Melatonin,149,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Oral pill within 7 days after procedure, no detail on total number of pills given"
9741,Randomized Clinical Trial,Shi 2021,[Shi 2021](evidence_tables.html#9741),[Shi 2021](evidence_tables.html#9741),Shi 2021-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,148,kq6_proph_meds,,,,,,proph_med_postop,,,,,,,,,,,,melatonin,3,7,,,,,,,,,,,,,,,"oral pill within 7 days after procedure, no detail on total number of pills given",
9977,Case-Control,Choi 2019,[Choi 2019](evidence_tables.html#9977),[Choi 2019](evidence_tables.html#9977),Choi 2019-1,1,,,,,Melatonin,16,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9977,Case-Control,Choi 2019,[Choi 2019](evidence_tables.html#9977),[Choi 2019](evidence_tables.html#9977),Choi 2019-2,2,,,,,Melatonin,42,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10036,Randomized Clinical Trial,Sauer 2014,[Sauer 2014](evidence_tables.html#10036),[Sauer 2014](evidence_tables.html#10036),Sauer 2014-1,1,,,,,Melatonin,370,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10036,Randomized Clinical Trial,Sauer 2014,[Sauer 2014](evidence_tables.html#10036),[Sauer 2014](evidence_tables.html#10036),Sauer 2014-2,2,,,,,Melatonin,367,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10075,Randomized Clinical Trial,Ottens 2014,[Ottens 2014](evidence_tables.html#10075),[Ottens 2014](evidence_tables.html#10075) ([Dieleman 2012](evidence_tables.html#16533)),Ottens 2014-1,1,,,,,Melatonin,138,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10075,Randomized Clinical Trial,Ottens 2014,[Ottens 2014](evidence_tables.html#10075),[Ottens 2014](evidence_tables.html#10075) ([Dieleman 2012](evidence_tables.html#16533)),Ottens 2014-2,2,,,,,Melatonin,140,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10090,Before-After/Time Series,Yamasaki 2019,[Yamasaki 2019](evidence_tables.html#10090),[Yamasaki 2019](evidence_tables.html#10090),Yamasaki 2019-1,1,,,,,Melatonin,11,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10090,Before-After/Time Series,Yamasaki 2019,[Yamasaki 2019](evidence_tables.html#10090),[Yamasaki 2019](evidence_tables.html#10090),Yamasaki 2019-2,2,,,,,Melatonin,10,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10515,Randomized Clinical Trial,Whitlock 2015,[Whitlock 2015](evidence_tables.html#10515),[Whitlock 2015](evidence_tables.html#10515),Whitlock 2015-1,1,,,,,Melatonin,3752,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10515,Randomized Clinical Trial,Whitlock 2015,[Whitlock 2015](evidence_tables.html#10515),[Whitlock 2015](evidence_tables.html#10515),Whitlock 2015-2,2,,,,,Melatonin,3755,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11129,Randomized Clinical Trial,Zhu 2021,[Zhu 2021](evidence_tables.html#11129),[Zhu 2021](evidence_tables.html#11129),Zhu 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,92,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Before anesthesia, 1 μg/kg of 0.9% sodium chloride injection was infused using a micropump for about 10 minutes. During the operation, 0.5 μg/kg/h of 0.9% sodium chloride injection was continuously pumped. Infusion stopped 10 min before end of procedure."
11129,Randomized Clinical Trial,Zhu 2021,[Zhu 2021](evidence_tables.html#11129),[Zhu 2021](evidence_tables.html#11129),Zhu 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,95,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,1,0.5,,,,,,,,,,,,,,,,,,,,,,,,,"before anesthesia, 1 μg/kg injection of dex was infused using a micropump for about 10 minutes. During the operation, 0.5 μg/kg/h  of dex was continuously pumped. Infusion stopped 10 min before end of procedure.",
11264,Before-After/Time Series,Lester 2022,[Lester 2022](evidence_tables.html#11264),[Lester 2022](evidence_tables.html#11264),Lester 2022-1,1,,,,,Dexmedetomidine,250,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11264,Before-After/Time Series,Lester 2022,[Lester 2022](evidence_tables.html#11264),[Lester 2022](evidence_tables.html#11264),Lester 2022-2,2,,,,,Dexmedetomidine,242,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11652,Randomized Clinical Trial,Forsmo 2016,[Forsmo 2016](evidence_tables.html#11652),[Forsmo 2016](evidence_tables.html#11652),Forsmo 2016-1,1,,,,,Dexmedetomidine,153,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11652,Randomized Clinical Trial,Forsmo 2016,[Forsmo 2016](evidence_tables.html#11652),[Forsmo 2016](evidence_tables.html#11652),Forsmo 2016-2,2,,,,,Dexmedetomidine,154,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12900,Randomized Clinical Trial,Tang 2021,[Tang 2021](evidence_tables.html#12900),[Tang 2021](evidence_tables.html#12900),Tang 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sodium chloride IV 15 min before induction until 40 min before end of surgery
12900,Randomized Clinical Trial,Tang 2021,[Tang 2021](evidence_tables.html#12900),[Tang 2021](evidence_tables.html#12900),Tang 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,50,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine IV (0.5 mcg/kg loading and 0.4 mcg/kg/h maintenance) 15 min before induction until 40 min before end of surgery,
13075,Randomized Clinical Trial,Xing 2021,[Xing 2021](evidence_tables.html#13075),[Xing 2021](evidence_tables.html#13075),Xing 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,55,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9% saline injection via an infusion pump for 15 min.
13075,Randomized Clinical Trial,Xing 2021,[Xing 2021](evidence_tables.html#13075),[Xing 2021](evidence_tables.html#13075),Xing 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,55,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,0.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
13116,Nonrandomized Trial,Zhou 2021,[Zhou 2021](evidence_tables.html#13116),[Zhou 2021](evidence_tables.html#13116),Zhou 2021-1,1,,,,,Dexmedetomidine,116,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13116,Nonrandomized Trial,Zhou 2021,[Zhou 2021](evidence_tables.html#13116),[Zhou 2021](evidence_tables.html#13116),Zhou 2021-2,2,,,,,Dexmedetomidine,149,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13133,Before-After/Time Series,Romano 2021,[Romano 2021](evidence_tables.html#13133),[Romano 2021](evidence_tables.html#13133),Romano 2021-1,1,,,,,Dexmedetomidine,59,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13133,Before-After/Time Series,Romano 2021,[Romano 2021](evidence_tables.html#13133),[Romano 2021](evidence_tables.html#13133),Romano 2021-2,2,,,,,Dexmedetomidine,122,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13141,Randomized Clinical Trial,Ren 2021,[Ren 2021](evidence_tables.html#13141),[Ren 2021](evidence_tables.html#13141),Ren 2021-1,1,,,,,Dexmedetomidine,154,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13141,Randomized Clinical Trial,Ren 2021,[Ren 2021](evidence_tables.html#13141),[Ren 2021](evidence_tables.html#13141),Ren 2021-2,2,,,,,Dexmedetomidine,127,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13184,Randomized Clinical Trial,Tu 2021,[Tu 2021](evidence_tables.html#13184),[Tu 2021](evidence_tables.html#13184),Tu 2021-1,1,Other,Control,Sufentanil,Suf,Ketamine,40,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sufentanil,,Anesthetic induction of propofol plus sufentanil
13184,Randomized Clinical Trial,Tu 2021,[Tu 2021](evidence_tables.html#13184),[Tu 2021](evidence_tables.html#13184),Tu 2021-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,40,kq6_proph_meds,,,,proph_med_induct,,,,,,,,,,ketamine,0.5,,,,,,,,,,,,,,,,,,,,anesthetic induction of propofol plus esketamine (0.5 mg/kg),
13301,Nonrandomized Trial,Li 2020a,[Li 2020a](evidence_tables.html#13301),[Li 2020a](evidence_tables.html#13301),Li 2020a-1,1,None,Control,None,None,Dexmedetomidine,46,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Conventional anesthesia (propofol, midazolam, sufentanil, cisatracurium besilate)"
13301,Nonrandomized Trial,Li 2020a,[Li 2020a](evidence_tables.html#13301),[Li 2020a](evidence_tables.html#13301),Li 2020a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,41,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.5,0.1,,,,,,,,,,,,,,,,,,,,,,,,,"conventional anesthesia (propofol, midazolam, sufentanil, cisatracurium besilate) plus dexmedetomidine (0.5 mcg/kg loading dose and 0.1 mcg/kg/h maintenance)",
13361,Nonrandomized Trial,Wang 2020c,[Wang 2020c](evidence_tables.html#13361),[Wang 2020c](evidence_tables.html#13361),Wang 2020c-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 ug/kg loading and 0.4 ug/kg/hr maintenance of 0.9% sodium chloride
13361,Nonrandomized Trial,Wang 2020c,[Wang 2020c](evidence_tables.html#13361),[Wang 2020c](evidence_tables.html#13361),Wang 2020c-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,60,kq6_proph_meds,,,proph_med_pre,,,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,"dexmedetomidine iv drip of 0.5 ug/kg loading dose, 0.4 ug/kg/hr maintenance dose",
13367,Retrospective Cohort,Yin 2020,[Yin 2020](evidence_tables.html#13367),[Yin 2020](evidence_tables.html#13367),Yin 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,58,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Saline administration, looks like both groups also received anesthesia induction of vecuronium bromide"
13367,Retrospective Cohort,Yin 2020,[Yin 2020](evidence_tables.html#13367),[Yin 2020](evidence_tables.html#13367),Yin 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,62,kq6_proph_meds,,,proph_med_pre,,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,"Dexmedetomidine injection, both groups had anesthetic induction of vecuronium bromide",
13368,Nonrandomized Trial,Zhang 2020b,[Zhang 2020b](evidence_tables.html#13368),[Zhang 2020b](evidence_tables.html#13368),Zhang 2020b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,46,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline administered intraoperatively
13368,Nonrandomized Trial,Zhang 2020b,[Zhang 2020b](evidence_tables.html#13368),[Zhang 2020b](evidence_tables.html#13368),Zhang 2020b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,57,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,0.5 mcg/kg/h dexmedetomidine administered right before induction through 15 min postsurgery,
13368,Nonrandomized Trial,Zhang 2020b,[Zhang 2020b](evidence_tables.html#13368),[Zhang 2020b](evidence_tables.html#13368),Zhang 2020b-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,62,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,,1,,,,,,,,,,,,,,,,,,,,,,,,,1.0 mcg/kg/h dexmedetomidine administered right before induction through 15 min postsurgery,
13393,Nonrandomized Trial,Bao 2020,[Bao 2020](evidence_tables.html#13393),[Bao 2020](evidence_tables.html#13393),Bao 2020-1,1,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine/Ulinastatin,Dex/Ulin,Dexmedetomidine,95,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.3,,,,,,,,,,,,,,,,,ulinastatin,2,,,,,,,"dexmedetomidine, 0.5 mcg/kg before induction, maintenance at 0.3 mcg/kg/h until 30 min before end of surgery, plus ulinastatin, 2 kU/kg bolus, maintenance 1 kU/kg/h until end of operation",
13393,Nonrandomized Trial,Bao 2020,[Bao 2020](evidence_tables.html#13393),[Bao 2020](evidence_tables.html#13393),Bao 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,83,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.3,,,,,,,,,,,,,,,,,,,,,,,,,"dexmedetomidine alone, 0.5 mcg/kg before induction, maintenance at 0.3 mcg/kg/h until 30 min before end of surgery",
13406,Randomized Clinical Trial,Zhou 2019b,[Zhou 2019b](evidence_tables.html#13406),[Zhou 2019b](evidence_tables.html#13406),Zhou 2019b-1,1,Placebo,Control,Placebo,Plac,Ulinastatin,38,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infusion after induction and first day after surgery
13406,Randomized Clinical Trial,Zhou 2019b,[Zhou 2019b](evidence_tables.html#13406),[Zhou 2019b](evidence_tables.html#13406),Zhou 2019b-2,2,Ulinastatin,Ulinastatin,Ulinastatin,Ulin,Ulinastatin,39,kq6_proph_meds,,,,,,,,,,,,,,,,,,,,,,,,,,,ulinastatin,20000,2,"ulinastatin infusion (20,000 UI/kg) after induction and first day after surgery",,,,,ulinastatin infusion,
13406,Randomized Clinical Trial,Zhou 2019b,[Zhou 2019b](evidence_tables.html#13406),[Zhou 2019b](evidence_tables.html#13406),Zhou 2019b-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine/Ulinastatin,Dex/Ulin,Dexmedetomidine,39,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,0.4,,,,,,,,,,,,,,,,,ulinastatin,20000,2,,,,,,"ulinastatin infusion (20,000 UI/kg) and dexmedetomidine infusion (0.4 mcg/kg/h) after induction until 2 h before extubation",
13406,Randomized Clinical Trial,Zhou 2019b,[Zhou 2019b](evidence_tables.html#13406),[Zhou 2019b](evidence_tables.html#13406),Zhou 2019b-4,4,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,38,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,0.4,,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine (0.4 mcg/kg/h) infusion after induction until 2 h before extubation,
13483,Randomized Clinical Trial,Wang 2019,[Wang 2019](evidence_tables.html#13483),[Wang 2019](evidence_tables.html#13483),Wang 2019-1,1,Other,Control,Midazolam,Mid,Dexmedetomidine,100,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,midazolam,,Midazolam loading dose (0.05 mg/kg)
13483,Randomized Clinical Trial,Wang 2019,[Wang 2019](evidence_tables.html#13483),[Wang 2019](evidence_tables.html#13483),Wang 2019-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,98,kq6_proph_meds,,,proph_med_pre,,,,,dexmedetomidine,0.5,,,,,,,,,,,,,,,,,,,,,"no maintenance dose, only loading dose for Dexmedetomidine",,,,,Dexmedetomidine injection prior to anesthesia,
13512,Randomized Clinical Trial,Gupta 2019,[Gupta 2019](evidence_tables.html#13512),[Gupta 2019](evidence_tables.html#13512),Gupta 2019-1,1,Placebo,Control,Placebo,Plac,Ramelteon,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo tablet one 12 hrs before surgery and one table 1 hour before surgery.
13512,Randomized Clinical Trial,Gupta 2019,[Gupta 2019](evidence_tables.html#13512),[Gupta 2019](evidence_tables.html#13512),Gupta 2019-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,50,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,,,,,,,,ramelteon,8,2,,,,,,,,,,,,one tablet 12 hrs before surgery and one table 1 hour before surgery.,
13546,Randomized Clinical Trial,Zhang 2018c,[Zhang 2018c](evidence_tables.html#13546),[Zhang 2018c](evidence_tables.html#13546),Zhang 2018c-1,1,Placebo,Control,Placebo,Plac,Ulinastatin,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100 ml normal saline (control group) was administered intravenously over a period of 30 min before surgical incision and 5000 units/kg was administered after surgery on the 1st and 2nd days.
13546,Randomized Clinical Trial,Zhang 2018c,[Zhang 2018c](evidence_tables.html#13546),[Zhang 2018c](evidence_tables.html#13546),Zhang 2018c-2,2,Ulinastatin,Ulinastatin,Ulinastatin,Ulin,Ulinastatin,30,kq6_proph_meds,,,,proph_med_induct,,proph_med_postop,,,,,,,,,,,,,,,,,,,,,ulinastatin,10000,,,,,,,"10,000 units/kg [diluted in normal saline to 100 ml (treatment group)] was administered intravenously over a period of 30 min
before surgical incision and 5000 units/kg was administered after surgery on the 1st and 2nd days.",
13568,Randomized Clinical Trial,He 2018,[He 2018](evidence_tables.html#13568),[He 2018](evidence_tables.html#13568),He 2018-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo,Intravenous injection of saline (same amount as the DEX in group A),,,Intravenous injection of saline (same amount as the DEX in group A)
13568,Randomized Clinical Trial,He 2018,[He 2018](evidence_tables.html#13568),[He 2018](evidence_tables.html#13568),He 2018-2,2,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam,,,,
13568,Randomized Clinical Trial,He 2018,[He 2018](evidence_tables.html#13568),[He 2018](evidence_tables.html#13568),He 2018-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,proph_med_pre,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,Dexmedetomidine,,,"pump injection of 0.5 mcg/kg dexmedetomidine for 10 minutes before anesthesia induction. Then the anesthesia induction began, while dexmedetomidine was maintained at 0.4 mcg/(kgxh) until the end of the operation.",
13579,Randomized Clinical Trial,Azeem 2018,[Azeem 2018](evidence_tables.html#13579),[Azeem 2018](evidence_tables.html#13579),Azeem 2018-1,1,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam,,,,
13579,Randomized Clinical Trial,Azeem 2018,[Azeem 2018](evidence_tables.html#13579),[Azeem 2018](evidence_tables.html#13579),Azeem 2018-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,0.4,0.7,,,,,,,,,,,,,,,,,,,,Dexmedetomidine,,,"dexmedetomidine was diluted in 5% dextrose. Per authors, loading dose is usually unnecessary and not recommended. Protocol shown in Figure 1 (dex infusion started at 0.4 to 0.7 mcg/kg/hr which was evaluated within 45-60 minutes, increase in dex infusion by 0.1 to 0.2 mcg/kg/hr every 30 min to a maximum of 1.4 mcg/kg/hr or bolus with either a selection between morphine 30 mcg/kg or fentanyl 20 mcg/kg or a selection between midazolam 15mcg/kg or propofol 20 mg.",
13669,Randomized Clinical Trial,Haghighi 2017,[Haghighi 2017](evidence_tables.html#13669),[Haghighi 2017](evidence_tables.html#13669),Haghighi 2017-1,1,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13669,Randomized Clinical Trial,Haghighi 2017,[Haghighi 2017](evidence_tables.html#13669),[Haghighi 2017](evidence_tables.html#13669),Haghighi 2017-2,2,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13719,Randomized Clinical Trial,Ozer 2017,[Ozer 2017](evidence_tables.html#13719),[Ozer 2017](evidence_tables.html#13719),Ozer 2017-1,1,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13719,Randomized Clinical Trial,Ozer 2017,[Ozer 2017](evidence_tables.html#13719),[Ozer 2017](evidence_tables.html#13719),Ozer 2017-2,2,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13731,Randomized Clinical Trial,Yu 2017,[Yu 2017](evidence_tables.html#13731),[Yu 2017](evidence_tables.html#13731),Yu 2017-1,1,Midazolam,Midazolam,Midazolam,Mid,Dexmedetomidine,46,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midazolam,,,,
13731,Randomized Clinical Trial,Yu 2017,[Yu 2017](evidence_tables.html#13731),[Yu 2017](evidence_tables.html#13731),Yu 2017-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,46,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.2,0.5,0.2,0.7,,,,,,,,,,,,,,,,,,,,Dexmedetomidine,,,dex given both preoperatively and to maintain anesthesia,
13777,Randomized Clinical Trial,Ge 2016,[Ge 2016](evidence_tables.html#13777),[Ge 2016](evidence_tables.html#13777),Ge 2016-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,24,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intravenously administered saline
13777,Randomized Clinical Trial,Ge 2016,[Ge 2016](evidence_tables.html#13777),[Ge 2016](evidence_tables.html#13777),Ge 2016-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,24,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.3,0.3,,,,,,,,,,,,,,,,,,,,,,,,,"intravenously administered 0.3 mcg/kg of dexmedetomidine 10 min prior to anesthesia, and then at a rate of 0.3 mcg/kg/h intraoperatively until 30 min prior to the completion of surgery.",
13824,Nonrandomized Trial,Bily 2015,[Bily 2015](evidence_tables.html#13824),[Bily 2015](evidence_tables.html#13824),Bily 2015-1,1,None,Control,None,None,Melatonin,250,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13824,Nonrandomized Trial,Bily 2015,[Bily 2015](evidence_tables.html#13824),[Bily 2015](evidence_tables.html#13824),Bily 2015-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,250,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,5,4,,,,,,,,,,,,,,,,
13941,Randomized Clinical Trial,Mohamed 2014,[Mohamed 2014](evidence_tables.html#13941),[Mohamed 2014](evidence_tables.html#13941),Mohamed 2014-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,25,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.9% normal saline at a rate of 0.4 ug/kg/h by a syringe pump maintained until the end of surgery
13941,Randomized Clinical Trial,Mohamed 2014,[Mohamed 2014](evidence_tables.html#13941),[Mohamed 2014](evidence_tables.html#13941),Mohamed 2014-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,25,kq6_proph_meds,,,proph_med_pre,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.17,0.4,,,,,,,,,,,,,,,,,,,,,,,,,"10 minutes before induction, a blinded study drug bolus infusion was stated at 1ug/kg/hr for 10 minutes intravenously. Demedetomidine infusion at a rate of 0.4 ug/kg/hr by a syringe pump maintained until the end of surgery.",
14006,Randomized Clinical Trial,Mardani 2013,[Mardani 2013](evidence_tables.html#14006),[Mardani 2013](evidence_tables.html#14006),Mardani 2013-1,1,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14006,Randomized Clinical Trial,Mardani 2013,[Mardani 2013](evidence_tables.html#14006),[Mardani 2013](evidence_tables.html#14006),Mardani 2013-2,2,,,,,Dexmedetomidine,43,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14441,Randomized Clinical Trial,Casati 2003,[Casati 2003](evidence_tables.html#14441),[Casati 2003](evidence_tables.html#14441),Casati 2003-1,1,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14441,Randomized Clinical Trial,Casati 2003,[Casati 2003](evidence_tables.html#14441),[Casati 2003](evidence_tables.html#14441),Casati 2003-2,2,,,,,Dexmedetomidine,15,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14566,Randomized Clinical Trial,Chu 2006,[Chu 2006](evidence_tables.html#14566),[Chu 2006](evidence_tables.html#14566),Chu 2006-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14566,Randomized Clinical Trial,Chu 2006,[Chu 2006](evidence_tables.html#14566),[Chu 2006](evidence_tables.html#14566),Chu 2006-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14821,Retrospective Cohort,Shimizu 2010,[Shimizu 2010](evidence_tables.html#14821),[Shimizu 2010](evidence_tables.html#14821),Shimizu 2010-1,1,,,,,Dexmedetomidine,84,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14821,Retrospective Cohort,Shimizu 2010,[Shimizu 2010](evidence_tables.html#14821),[Shimizu 2010](evidence_tables.html#14821),Shimizu 2010-2,2,,,,,Dexmedetomidine,84,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15278,Randomized Clinical Trial,Apan 2016,[Apan 2016](evidence_tables.html#15278),[Apan 2016](evidence_tables.html#15278),Apan 2016-1,1,,,,,Dexmedetomidine,25,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15278,Randomized Clinical Trial,Apan 2016,[Apan 2016](evidence_tables.html#15278),[Apan 2016](evidence_tables.html#15278),Apan 2016-2,2,,,,,Dexmedetomidine,25,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15285,Randomized Clinical Trial,Bornemann-Cimenti 2016,[Bornemann-Cimenti 2016](evidence_tables.html#15285),[Bornemann-Cimenti 2016](evidence_tables.html#15285),Bornemann-Cimenti 2016-1,1,Placebo,Control,Placebo,Plac,Ketamine,19,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IV saline infusion after induction through 48 hours
15285,Randomized Clinical Trial,Bornemann-Cimenti 2016,[Bornemann-Cimenti 2016](evidence_tables.html#15285),[Bornemann-Cimenti 2016](evidence_tables.html#15285),Bornemann-Cimenti 2016-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,19,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,,,,,,,ketamine,,0.015,,,,,,,,,,,,,,,,,,,IV saline bolus at induction followed by continuous infusion 0.015 mg/kg/h ketamine for 48 h postsurgery,
15285,Randomized Clinical Trial,Bornemann-Cimenti 2016,[Bornemann-Cimenti 2016](evidence_tables.html#15285),[Bornemann-Cimenti 2016](evidence_tables.html#15285),Bornemann-Cimenti 2016-3,3,Ketamine,Ketamine,Ketamine,Ket,Ketamine,18,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,,,,,,,ketamine,0.25,0.125,,,,,,,,,,,,,,,,,,,IV 0.25 mg/kg bolus at induction followed by continuous infusion 0.125 mg/kg/h S-ketamine for 48 h postsurgery,
15331,Retrospective Cohort,Koo 2016,[Koo 2016](evidence_tables.html#15331),[Koo 2016](evidence_tables.html#15331),Koo 2016-1,1,,,,,Ketamine,390,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15331,Retrospective Cohort,Koo 2016,[Koo 2016](evidence_tables.html#15331),[Koo 2016](evidence_tables.html#15331),Koo 2016-2,2,,,,,Ketamine,390,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15440,Randomized Clinical Trial,Fazel 2017,[Fazel 2017](evidence_tables.html#15440),[Fazel 2017](evidence_tables.html#15440),Fazel 2017-1,1,,,,,Ketamine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15440,Randomized Clinical Trial,Fazel 2017,[Fazel 2017](evidence_tables.html#15440),[Fazel 2017](evidence_tables.html#15440),Fazel 2017-2,2,,,,,Ketamine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16008,Randomized Clinical Trial,Turan 2020,[Turan 2020](evidence_tables.html#16008),[Turan 2020](evidence_tables.html#16008),Turan 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,396,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Saline infusion started at incision 0.1 ug/kg/h, end of bypass increased to 0.2 ug/kg/h, increased again to 0.4 ug/kg/h postoperatively"
16008,Randomized Clinical Trial,Turan 2020,[Turan 2020](evidence_tables.html#16008),[Turan 2020](evidence_tables.html#16008),Turan 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,398,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,proph_med_postop,,dexmedetomidine,,0.1,,0.2,0.4,,,,,,,,,,,,,,,,,,,,,,"infusion started at incision 0.1 ug/kg/h, end of bypass increased to 0.2 ug/kg/h, increased again to 0.4 ug/kg/h postoperatively",
16023,Randomized Clinical Trial,Wu 2020,[Wu 2020](evidence_tables.html#16023),[Wu 2020](evidence_tables.html#16023),Wu 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,40,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline given at induction and infused until end of surgery
16023,Randomized Clinical Trial,Wu 2020,[Wu 2020](evidence_tables.html#16023),[Wu 2020](evidence_tables.html#16023),Wu 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,40,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.6,,,,,,,,,,,,,,,,,,,,,,,,,given at induction and infused until end of surgery,
16303,Randomized Clinical Trial,Yan 2021,[Yan 2021](evidence_tables.html#16303),[Yan 2021](evidence_tables.html#16303),Yan 2021-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,50,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Infused with normal saline from 5 mins before induction to end of surgery
16303,Randomized Clinical Trial,Yan 2021,[Yan 2021](evidence_tables.html#16303),[Yan 2021](evidence_tables.html#16303),Yan 2021-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,50,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,,0.3,,,,,,,,,,,,,,,,,,,,,,,,,infusion from 5 min before induction to end of surgery,
16533,Randomized Clinical Trial,Dieleman 2012,[Dieleman 2012](evidence_tables.html#16533),[Dieleman 2012](evidence_tables.html#16533),Dieleman 2012-1,1,,,,,Dexmedetomidine,2247,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16533,Randomized Clinical Trial,Dieleman 2012,[Dieleman 2012](evidence_tables.html#16533),[Dieleman 2012](evidence_tables.html#16533),Dieleman 2012-2,2,,,,,Dexmedetomidine,2235,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16537,Nonrandomized Trial,Artemiou 2015,[Artemiou 2015](evidence_tables.html#16537),[Artemiou 2015](evidence_tables.html#16537),Artemiou 2015-1,1,None,Control,None,None,Melatonin,250,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16537,Nonrandomized Trial,Artemiou 2015,[Artemiou 2015](evidence_tables.html#16537),[Artemiou 2015](evidence_tables.html#16537),Artemiou 2015-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,250,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,5,4,,,,,,,,,,,,,,,,
16539,Before-After/Time Series,Bakker 2014,[Bakker 2014](evidence_tables.html#16539),[Bakker 2014](evidence_tables.html#16539),Bakker 2014-1,1,,,,,Melatonin,120,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16539,Before-After/Time Series,Bakker 2014,[Bakker 2014](evidence_tables.html#16539),[Bakker 2014](evidence_tables.html#16539),Bakker 2014-2,2,,,,,Melatonin,121,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16544,Before-After/Time Series,Bjorkelund 2010,[Bjorkelund 2010](evidence_tables.html#16544),[Bjorkelund 2010](evidence_tables.html#16544),Bjorkelund 2010-1,1,,,,,Melatonin,132,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16544,Before-After/Time Series,Bjorkelund 2010,[Bjorkelund 2010](evidence_tables.html#16544),[Bjorkelund 2010](evidence_tables.html#16544),Bjorkelund 2010-2,2,,,,,Melatonin,131,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16547,Randomized Clinical Trial,Celik 2011,[Celik 2011](evidence_tables.html#16547),[Celik 2011](evidence_tables.html#16547),Celik 2011-1,1,,,,,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16547,Randomized Clinical Trial,Celik 2011,[Celik 2011](evidence_tables.html#16547),[Celik 2011](evidence_tables.html#16547),Celik 2011-2,2,,,,,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16552,Randomized Clinical Trial,de Jonghe 2014,[de Jonghe 2014](evidence_tables.html#16552),[de Jonghe 2014](evidence_tables.html#16552),de Jonghe 2014-1,1,Placebo,Control,Placebo,Plac,Melatonin,192,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16552,Randomized Clinical Trial,de Jonghe 2014,[de Jonghe 2014](evidence_tables.html#16552),[de Jonghe 2014](evidence_tables.html#16552),de Jonghe 2014-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,186,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,3,5,,,,,,,,,,,,,,,"after randomization patients received the study medication on 5 consecutive evenings, starting the day of admission at about 9 pm.",
16556,Randomized Clinical Trial,Egawa 2016,[Egawa 2016](evidence_tables.html#16556),[Egawa 2016](evidence_tables.html#16556),Egawa 2016-1,1,,,,,Melatonin,72,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16556,Randomized Clinical Trial,Egawa 2016,[Egawa 2016](evidence_tables.html#16556),[Egawa 2016](evidence_tables.html#16556),Egawa 2016-2,2,,,,,Melatonin,72,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16557,Randomized Clinical Trial,Epple 2001,[Epple 2001](evidence_tables.html#16557),[Epple 2001](evidence_tables.html#16557),Epple 2001-1,1,,,,,Melatonin,62,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16557,Randomized Clinical Trial,Epple 2001,[Epple 2001](evidence_tables.html#16557),[Epple 2001](evidence_tables.html#16557),Epple 2001-2,2,,,,,Melatonin,62,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16558,Randomized Clinical Trial,Ford 2020,[Ford 2020](evidence_tables.html#16558),[Ford 2020](evidence_tables.html#16558),Ford 2020-1,1,Placebo,Control,Placebo,Plac,Melatonin,104,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"7 consecutive nights of placebo, starting 2 days prior to surgery (orally or via nasogastric tube for those unable to swallow)"
16558,Randomized Clinical Trial,Ford 2020,[Ford 2020](evidence_tables.html#16558),[Ford 2020](evidence_tables.html#16558),Ford 2020-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,98,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,3,7,,,,,,,,,,,,,,,"7 consecutive nights of melatonin (3 mg), starting 2 days prior to surgery (orally or via nasogastric tube for those unable to swallow)",
16559,Randomized Clinical Trial,Geng 2017,[Geng 2017](evidence_tables.html#16559),[Geng 2017](evidence_tables.html#16559),Geng 2017-1,1,,,,,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16559,Randomized Clinical Trial,Geng 2017,[Geng 2017](evidence_tables.html#16559),[Geng 2017](evidence_tables.html#16559),Geng 2017-2,2,,,,,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16559,Randomized Clinical Trial,Geng 2017,[Geng 2017](evidence_tables.html#16559),[Geng 2017](evidence_tables.html#16559),Geng 2017-3,3,,,,,Melatonin,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16572,Randomized Clinical Trial,Ishii 2016,[Ishii 2016](evidence_tables.html#16572),[Ishii 2016](evidence_tables.html#16572),Ishii 2016-1,1,,,,,Melatonin,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16572,Randomized Clinical Trial,Ishii 2016,[Ishii 2016](evidence_tables.html#16572),[Ishii 2016](evidence_tables.html#16572),Ishii 2016-2,2,,,,,Melatonin,29,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16573,Randomized Clinical Trial,Jia 2014,[Jia 2014](evidence_tables.html#16573),[Jia 2014](evidence_tables.html#16573),Jia 2014-1,1,,,,,Melatonin,116,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16573,Randomized Clinical Trial,Jia 2014,[Jia 2014](evidence_tables.html#16573),[Jia 2014](evidence_tables.html#16573),Jia 2014-2,2,,,,,Melatonin,117,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16587,Randomized Clinical Trial,Luntz 2004,[Luntz 2004](evidence_tables.html#16587),[Luntz 2004](evidence_tables.html#16587),Luntz 2004-1,1,,,,,Melatonin,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16587,Randomized Clinical Trial,Luntz 2004,[Luntz 2004](evidence_tables.html#16587),[Luntz 2004](evidence_tables.html#16587),Luntz 2004-2,2,,,,,Melatonin,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16587,Randomized Clinical Trial,Luntz 2004,[Luntz 2004](evidence_tables.html#16587),[Luntz 2004](evidence_tables.html#16587),Luntz 2004-3,3,,,,,Melatonin,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16591,Before-After/Time Series,McDonald 2018,[McDonald 2018](evidence_tables.html#16591),[McDonald 2018](evidence_tables.html#16591),McDonald 2018-1,1,,,,,Melatonin,143,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16591,Before-After/Time Series,McDonald 2018,[McDonald 2018](evidence_tables.html#16591),[McDonald 2018](evidence_tables.html#16591),McDonald 2018-2,2,,,,,Melatonin,183,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16601,Before-After/Time Series,Olsson 2014,[Olsson 2014](evidence_tables.html#16601),[Olsson 2014](evidence_tables.html#16601),Olsson 2014-1,1,,,,,Melatonin,138,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16601,Before-After/Time Series,Olsson 2014,[Olsson 2014](evidence_tables.html#16601),[Olsson 2014](evidence_tables.html#16601),Olsson 2014-2,2,,,,,Melatonin,128,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16605,Randomized Clinical Trial,Partridge 2017,[Partridge 2017](evidence_tables.html#16605),[Partridge 2017](evidence_tables.html#16605),Partridge 2017-1,1,,,,,Melatonin,105,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16605,Randomized Clinical Trial,Partridge 2017,[Partridge 2017](evidence_tables.html#16605),[Partridge 2017](evidence_tables.html#16605),Partridge 2017-2,2,,,,,Melatonin,104,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16607,Randomized Clinical Trial,Prakanrattana 2007,[Prakanrattana 2007](evidence_tables.html#16607),[Prakanrattana 2007](evidence_tables.html#16607),Prakanrattana 2007-1,1,,,,,Melatonin,63,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16607,Randomized Clinical Trial,Prakanrattana 2007,[Prakanrattana 2007](evidence_tables.html#16607),[Prakanrattana 2007](evidence_tables.html#16607),Prakanrattana 2007-2,2,,,,,Melatonin,63,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16608,Randomized Clinical Trial,Prestmo 2015,[Prestmo 2015](evidence_tables.html#16608),[Prestmo 2015](evidence_tables.html#16608),Prestmo 2015-1,1,,,,,Melatonin,199,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16608,Randomized Clinical Trial,Prestmo 2015,[Prestmo 2015](evidence_tables.html#16608),[Prestmo 2015](evidence_tables.html#16608),Prestmo 2015-2,2,,,,,Melatonin,198,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16622,Randomized Clinical Trial,Tang 2014,[Tang 2014](evidence_tables.html#16622),[Tang 2014](evidence_tables.html#16622),Tang 2014-1,1,,,,,Melatonin,99,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16622,Randomized Clinical Trial,Tang 2014,[Tang 2014](evidence_tables.html#16622),[Tang 2014](evidence_tables.html#16622),Tang 2014-2,2,,,,,Melatonin,101,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16623,Retrospective Cohort,Tarazona-Santabalbina 2019,[Tarazona-Santabalbina 2019](evidence_tables.html#16623),[Tarazona-Santabalbina 2019](evidence_tables.html#16623),Tarazona-Santabalbina 2019-1,1,,,,,Melatonin,107,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16623,Retrospective Cohort,Tarazona-Santabalbina 2019,[Tarazona-Santabalbina 2019](evidence_tables.html#16623),[Tarazona-Santabalbina 2019](evidence_tables.html#16623),Tarazona-Santabalbina 2019-2,2,,,,,Melatonin,203,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16628,Randomized Clinical Trial,Vidan 2005,[Vidan 2005](evidence_tables.html#16628),[Vidan 2005](evidence_tables.html#16628),Vidan 2005-1,1,,,,,Melatonin,164,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16628,Randomized Clinical Trial,Vidan 2005,[Vidan 2005](evidence_tables.html#16628),[Vidan 2005](evidence_tables.html#16628),Vidan 2005-2,2,,,,,Melatonin,155,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16629,Before-After/Time Series,Vochteloo 2011,[Vochteloo 2011](evidence_tables.html#16629),[Vochteloo 2011](evidence_tables.html#16629),Vochteloo 2011-1,1,,,,,Melatonin,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16629,Before-After/Time Series,Vochteloo 2011,[Vochteloo 2011](evidence_tables.html#16629),[Vochteloo 2011](evidence_tables.html#16629),Vochteloo 2011-2,2,,,,,Melatonin,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16629,Before-After/Time Series,Vochteloo 2011,[Vochteloo 2011](evidence_tables.html#16629),[Vochteloo 2011](evidence_tables.html#16629),Vochteloo 2011-3,3,,,,,Melatonin,,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16629,Before-After/Time Series,Vochteloo 2011,[Vochteloo 2011](evidence_tables.html#16629),[Vochteloo 2011](evidence_tables.html#16629),Vochteloo 2011-4,4,,,,,Melatonin,378,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16714,Retrospective Cohort,Park 2022,[Park 2022](evidence_tables.html#16714),[Park 2022](evidence_tables.html#16714),Park 2022-1,1,,,,,Melatonin,118936,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16714,Retrospective Cohort,Park 2022,[Park 2022](evidence_tables.html#16714),[Park 2022](evidence_tables.html#16714),Park 2022-2,2,,,,,Melatonin,118936,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16718,Randomized Clinical Trial,Lv 2022,[Lv 2022](evidence_tables.html#16718),[Lv 2022](evidence_tables.html#16718),Lv 2022-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,157,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline IV within 72 h postsurgery
16718,Randomized Clinical Trial,Lv 2022,[Lv 2022](evidence_tables.html#16718),[Lv 2022](evidence_tables.html#16718),Lv 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,152,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,0.1,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine IV within 72 h postsurgery,
16726,Randomized Clinical Trial,Liang 2022,[Liang 2022](evidence_tables.html#16726),[Liang 2022](evidence_tables.html#16726),Liang 2022-1,1,,,,,Dexmedetomidine,70,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16726,Randomized Clinical Trial,Liang 2022,[Liang 2022](evidence_tables.html#16726),[Liang 2022](evidence_tables.html#16726),Liang 2022-2,2,,,,,Dexmedetomidine,70,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16734,Randomized Clinical Trial,Wang 2022b,[Wang 2022b](evidence_tables.html#16734),[Wang 2022b](evidence_tables.html#16734),Wang 2022b-1,1,None,Control,None,None,Dexmedetomidine,40,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Standard anesthesia
16734,Randomized Clinical Trial,Wang 2022b,[Wang 2022b](evidence_tables.html#16734),[Wang 2022b](evidence_tables.html#16734),Wang 2022b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,42,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.6,,,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine added to standard anesthesia,
16739,Randomized Clinical Trial,Zhu 2022,[Zhu 2022](evidence_tables.html#16739),[Zhu 2022](evidence_tables.html#16739),Zhu 2022-1,1,,,,,Dexmedetomidine,85,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16739,Randomized Clinical Trial,Zhu 2022,[Zhu 2022](evidence_tables.html#16739),[Zhu 2022](evidence_tables.html#16739),Zhu 2022-2,2,,,,,Dexmedetomidine,70,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16741,Randomized Clinical Trial,Liu 2022a,[Liu 2022a](evidence_tables.html#16741),[Liu 2022a](evidence_tables.html#16741),Liu 2022a-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,31,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline IV started for 20 minutes prior to induction
16741,Randomized Clinical Trial,Liu 2022a,[Liu 2022a](evidence_tables.html#16741),[Liu 2022a](evidence_tables.html#16741),Liu 2022a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,29,kq6_proph_meds,,,,proph_med_induct,,,,dexmedetomidine,1,,,,,,,,,,,,,,,,,,,,,,,,,,"dexmedetomidine IV started for 20 minutes prior to induction, 1 mcg/kg",
16830,Retrospective Cohort,Xu 2022,[Xu 2022](evidence_tables.html#16830),[Xu 2022](evidence_tables.html#16830),Xu 2022-1,1,None,Control,None,None,Dexmedetomidine,30,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16830,Retrospective Cohort,Xu 2022,[Xu 2022](evidence_tables.html#16830),[Xu 2022](evidence_tables.html#16830),Xu 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,
16845,Randomized Clinical Trial,Liu 2022b,[Liu 2022b](evidence_tables.html#16845),[Liu 2022b](evidence_tables.html#16845),Liu 2022b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,60,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Normal saline at induction, followed by continuous infusion at 0.4 ug/kg/h until 30 min before end of surgery."
16845,Randomized Clinical Trial,Liu 2022b,[Liu 2022b](evidence_tables.html#16845),[Liu 2022b](evidence_tables.html#16845),Liu 2022b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,60,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,
16846,Before-After/Time Series,Giannotti 2022,[Giannotti 2022](evidence_tables.html#16846),[Giannotti 2022](evidence_tables.html#16846),Giannotti 2022-1,1,,,,,Dexmedetomidine,117,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16846,Before-After/Time Series,Giannotti 2022,[Giannotti 2022](evidence_tables.html#16846),[Giannotti 2022](evidence_tables.html#16846),Giannotti 2022-2,2,,,,,Dexmedetomidine,90,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16890,Retrospective Cohort,Yoshimura 2022,[Yoshimura 2022](evidence_tables.html#16890),[Yoshimura 2022](evidence_tables.html#16890),Yoshimura 2022-1,1,,,,,Dexmedetomidine,427695,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16890,Retrospective Cohort,Yoshimura 2022,[Yoshimura 2022](evidence_tables.html#16890),[Yoshimura 2022](evidence_tables.html#16890),Yoshimura 2022-2,2,,,,,Dexmedetomidine,142565,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16931,Randomized Clinical Trial,Qiao 2023,[Qiao 2023](evidence_tables.html#16931),[Qiao 2023](evidence_tables.html#16931),Qiao 2023-1,1,,,,,Dexmedetomidine,31,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16931,Randomized Clinical Trial,Qiao 2023,[Qiao 2023](evidence_tables.html#16931),[Qiao 2023](evidence_tables.html#16931),Qiao 2023-2,2,,,,,Dexmedetomidine,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16961,Retrospective Cohort,Koch 2023,[Koch 2023](evidence_tables.html#16961),[Koch 2023](evidence_tables.html#16961),Koch 2023-1,1,,,,,Dexmedetomidine,1001,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16961,Retrospective Cohort,Koch 2023,[Koch 2023](evidence_tables.html#16961),[Koch 2023](evidence_tables.html#16961),Koch 2023-2,2,,,,,Dexmedetomidine,57,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16970,Prospective Cohort,Aoki 2023,[Aoki 2023](evidence_tables.html#16970),[Aoki 2023](evidence_tables.html#16970),Aoki 2023-1,1,,,,,Dexmedetomidine,124,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16970,Prospective Cohort,Aoki 2023,[Aoki 2023](evidence_tables.html#16970),[Aoki 2023](evidence_tables.html#16970),Aoki 2023-2,2,,,,,Dexmedetomidine,76,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17001,Randomized Clinical Trial,Shin 2023,[Shin 2023](evidence_tables.html#17001),[Shin 2023](evidence_tables.html#17001),Shin 2023-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,366,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propofol,,Continuous infusion through end of surgery
17001,Randomized Clinical Trial,Shin 2023,[Shin 2023](evidence_tables.html#17001),[Shin 2023](evidence_tables.html#17001),Shin 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,366,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,1,,0.1,0.5,,,,,,,,,,,,,,,,,,,,,,,,
17006,Retrospective Cohort,Burfeind 2022,[Burfeind 2022](evidence_tables.html#17006),[Burfeind 2022](evidence_tables.html#17006),Burfeind 2022-1,1,,,,,Dexmedetomidine,417,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17006,Retrospective Cohort,Burfeind 2022,[Burfeind 2022](evidence_tables.html#17006),[Burfeind 2022](evidence_tables.html#17006),Burfeind 2022-2,2,,,,,Dexmedetomidine,1006,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17006,Retrospective Cohort,Burfeind 2022,[Burfeind 2022](evidence_tables.html#17006),[Burfeind 2022](evidence_tables.html#17006),Burfeind 2022-3,3,,,,,Dexmedetomidine,74,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17006,Retrospective Cohort,Burfeind 2022,[Burfeind 2022](evidence_tables.html#17006),[Burfeind 2022](evidence_tables.html#17006),Burfeind 2022-4,4,,,,,Dexmedetomidine,104,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17019,Randomized Clinical Trial,Qu 2023,[Qu 2023](evidence_tables.html#17019),[Qu 2023](evidence_tables.html#17019),Qu 2023-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,206,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A nighttime dose administered through IV following extubation on the night of surgery and every night up to 3 days postop.
17019,Randomized Clinical Trial,Qu 2023,[Qu 2023](evidence_tables.html#17019),[Qu 2023](evidence_tables.html#17019),Qu 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,188,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,,,1,,,,,,,,,,,,,,,,,,,,,,nighttime dose administered for 3 days in ICU.,
17038,Retrospective Cohort,Liu 2023a,[Liu 2023a](evidence_tables.html#17038),[Liu 2023a](evidence_tables.html#17038),Liu 2023a-1,1,,,,,Dexmedetomidine,50,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17038,Retrospective Cohort,Liu 2023a,[Liu 2023a](evidence_tables.html#17038),[Liu 2023a](evidence_tables.html#17038),Liu 2023a-2,2,,,,,Dexmedetomidine,145,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17055,Randomized Clinical Trial,Dianatkhah 2015,[Dianatkhah 2015](evidence_tables.html#17055),[Dianatkhah 2015](evidence_tables.html#17055),Dianatkhah 2015-1,1,Oxazepam,Oxazepam,Oxazepam,Oxaz,Melatonin,71,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oxazepam,,,,
17055,Randomized Clinical Trial,Dianatkhah 2015,[Dianatkhah 2015](evidence_tables.html#17055),[Dianatkhah 2015](evidence_tables.html#17055),Dianatkhah 2015-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,66,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,3,10,,,,,,,,,,,,Melatonin,,,"3 mg melatonin1 h prior to sleep time, 3 days before surgery through discharge",
17057,Randomized Clinical Trial,El-Naggar 2018,[El-Naggar 2018](evidence_tables.html#17057),[El-Naggar 2018](evidence_tables.html#17057),El-Naggar 2018-1,1,Placebo,Control,Placebo,Plac,Melatonin,25,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Placebo, 3 mg night before surgery, 30 min before surgery, evening after surgery, and evening 3 days postsurgery"
17057,Randomized Clinical Trial,El-Naggar 2018,[El-Naggar 2018](evidence_tables.html#17057),[El-Naggar 2018](evidence_tables.html#17057),El-Naggar 2018-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,25,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,3,5,,,,,,,,,,,,,,,"melatonin, 3 mg night before surgery, 30 min before surgery, evening after surgery, and evening 3 days postsurgery",
17080,Prospective Cohort,Deiner 2014,[Deiner 2014](evidence_tables.html#17080),[Deiner 2014](evidence_tables.html#17080),Deiner 2014-1,1,,,,,Melatonin,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17080,Prospective Cohort,Deiner 2014,[Deiner 2014](evidence_tables.html#17080),[Deiner 2014](evidence_tables.html#17080),Deiner 2014-2,2,,,,,Melatonin,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17084,Randomized Clinical Trial,Tanifuji 2022,[Tanifuji 2022](evidence_tables.html#17084),[Tanifuji 2022](evidence_tables.html#17084),Tanifuji 2022-1,1,Placebo,Control,Placebo,Plac,Ramelteon,19,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Placebo, administered 2 h before bedtime for 2 wks prior to surgery"
17084,Randomized Clinical Trial,Tanifuji 2022,[Tanifuji 2022](evidence_tables.html#17084),[Tanifuji 2022](evidence_tables.html#17084),Tanifuji 2022-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,23,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,,,,,,,,ramelteon,4,14,,,,,,,,,,,,"4 mg ramelteon, administered 2 h before bedtime for 2 wks prior to surgery",
17087,Nonrandomized Trial,Deschodt 2011,[Deschodt 2011](evidence_tables.html#17087),[Deschodt 2011](evidence_tables.html#17087),Deschodt 2011-1,1,,,,,Ramelteon,77,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17087,Nonrandomized Trial,Deschodt 2011,[Deschodt 2011](evidence_tables.html#17087),[Deschodt 2011](evidence_tables.html#17087),Deschodt 2011-2,2,,,,,Ramelteon,94,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17100,Randomized Clinical Trial,Neuman 2022,[Neuman 2022](evidence_tables.html#17100),[Neuman 2022](evidence_tables.html#17100) ([Neuman 2021](evidence_tables.html#8117)),Neuman 2022-1,1,,,,,Ramelteon,796,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17100,Randomized Clinical Trial,Neuman 2022,[Neuman 2022](evidence_tables.html#17100),[Neuman 2022](evidence_tables.html#17100) ([Neuman 2021](evidence_tables.html#8117)),Neuman 2022-2,2,,,,,Ramelteon,785,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17101,Randomized Clinical Trial,Cao 2023,[Cao 2023](evidence_tables.html#17101),[Cao 2023](evidence_tables.html#17101),Cao 2023-1,1,,,,,Ramelteon,597,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17101,Randomized Clinical Trial,Cao 2023,[Cao 2023](evidence_tables.html#17101),[Cao 2023](evidence_tables.html#17101),Cao 2023-2,2,,,,,Ramelteon,598,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17128,Prospective Cohort,Jones 2021,[Jones 2021](evidence_tables.html#17128),[Jones 2021](evidence_tables.html#17128),Jones 2021-1,1,,,,,Ramelteon,308,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17128,Prospective Cohort,Jones 2021,[Jones 2021](evidence_tables.html#17128),[Jones 2021](evidence_tables.html#17128),Jones 2021-2,2,,,,,Ramelteon,158,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17130,Retrospective Cohort,Memtsoudis 2019b,[Memtsoudis 2019b](evidence_tables.html#17130),[Memtsoudis 2019b](evidence_tables.html#17130) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019b-1,1,None,Control,None,None,Ketamine,538559,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,No ketamine
17130,Retrospective Cohort,Memtsoudis 2019b,[Memtsoudis 2019b](evidence_tables.html#17130),[Memtsoudis 2019b](evidence_tables.html#17130) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019b-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,25667,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,ketamine on day of surgery and/or postop day 1,
17131,Retrospective Cohort,Memtsoudis 2019c,[Memtsoudis 2019c](evidence_tables.html#17131),[Memtsoudis 2019c](evidence_tables.html#17131) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019c-1,1,,,,,Ketamine,542536,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17131,Retrospective Cohort,Memtsoudis 2019c,[Memtsoudis 2019c](evidence_tables.html#17131),[Memtsoudis 2019c](evidence_tables.html#17131) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019c-2,2,,,,,Ketamine,21690,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17132,Retrospective Cohort,Memtsoudis 2019d,[Memtsoudis 2019d](evidence_tables.html#17132),[Memtsoudis 2019d](evidence_tables.html#17132) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019d-1,1,,,,,Ketamine,309921,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17132,Retrospective Cohort,Memtsoudis 2019d,[Memtsoudis 2019d](evidence_tables.html#17132),[Memtsoudis 2019d](evidence_tables.html#17132) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019d-2,2,,,,,Ketamine,254305,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17133,Retrospective Cohort,Memtsoudis 2019e,[Memtsoudis 2019e](evidence_tables.html#17133),[Memtsoudis 2019e](evidence_tables.html#17133) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019e-1,1,,,,,Ketamine,344467,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17133,Retrospective Cohort,Memtsoudis 2019e,[Memtsoudis 2019e](evidence_tables.html#17133),[Memtsoudis 2019e](evidence_tables.html#17133) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019e-2,2,,,,,Ketamine,219759,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17134,Retrospective Cohort,Memtsoudis 2019f,[Memtsoudis 2019f](evidence_tables.html#17134),[Memtsoudis 2019f](evidence_tables.html#17134) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019f-1,1,,,,,Ketamine,175288,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17134,Retrospective Cohort,Memtsoudis 2019f,[Memtsoudis 2019f](evidence_tables.html#17134),[Memtsoudis 2019f](evidence_tables.html#17134) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019f-2,2,,,,,Ketamine,778956,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17134,Retrospective Cohort,Memtsoudis 2019f,[Memtsoudis 2019f](evidence_tables.html#17134),[Memtsoudis 2019f](evidence_tables.html#17134) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019f-3,3,,,,,Ketamine,25667,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17134,Retrospective Cohort,Memtsoudis 2019f,[Memtsoudis 2019f](evidence_tables.html#17134),[Memtsoudis 2019f](evidence_tables.html#17134) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019f-4,4,,,,,Ketamine,150658,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17136,Retrospective Cohort,Memtsoudis 2019g,[Memtsoudis 2019g](evidence_tables.html#17136),[Memtsoudis 2019g](evidence_tables.html#17136) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019g-1,1,None,Control,None,None,Ketamine,1081139,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,No ketamine
17136,Retrospective Cohort,Memtsoudis 2019g,[Memtsoudis 2019g](evidence_tables.html#17136),[Memtsoudis 2019g](evidence_tables.html#17136) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019g-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,49430,kq6_proph_meds,,,,,proph_med_intra,proph_med_postop,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,ketamine on day of surgery and/or postop day 1,
17137,Retrospective Cohort,Memtsoudis 2019h,[Memtsoudis 2019h](evidence_tables.html#17137),[Memtsoudis 2019h](evidence_tables.html#17137) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019h-1,1,,,,,Ketamine,1082854,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17137,Retrospective Cohort,Memtsoudis 2019h,[Memtsoudis 2019h](evidence_tables.html#17137),[Memtsoudis 2019h](evidence_tables.html#17137) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019h-2,2,,,,,Ketamine,47715,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17138,Retrospective Cohort,Memtsoudis 2019i,[Memtsoudis 2019i](evidence_tables.html#17138),[Memtsoudis 2019i](evidence_tables.html#17138) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019i-1,1,,,,,Ketamine,569339,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17138,Retrospective Cohort,Memtsoudis 2019i,[Memtsoudis 2019i](evidence_tables.html#17138),[Memtsoudis 2019i](evidence_tables.html#17138) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019i-2,2,,,,,Ketamine,561230,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17139,Retrospective Cohort,Memtsoudis 2019j,[Memtsoudis 2019j](evidence_tables.html#17139),[Memtsoudis 2019j](evidence_tables.html#17139) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019j-1,1,,,,,Ketamine,710381,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17139,Retrospective Cohort,Memtsoudis 2019j,[Memtsoudis 2019j](evidence_tables.html#17139),[Memtsoudis 2019j](evidence_tables.html#17139) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019j-2,2,,,,,Ketamine,420188,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17140,Retrospective Cohort,Slor 2011a,[Slor 2011a](evidence_tables.html#17140),[Slor 2011a](evidence_tables.html#17140) ([Kalisvaart 2005](evidence_tables.html#8574)),Slor 2011a-1,1,,,,,Ketamine,96,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17140,Retrospective Cohort,Slor 2011a,[Slor 2011a](evidence_tables.html#17140),[Slor 2011a](evidence_tables.html#17140) ([Kalisvaart 2005](evidence_tables.html#8574)),Slor 2011a-2,2,,,,,Ketamine,430,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17141,Retrospective Cohort,Slor 2011b,[Slor 2011b](evidence_tables.html#17141),[Slor 2011b](evidence_tables.html#17141) ([Kalisvaart 2005](evidence_tables.html#8574)),Slor 2011b-1,1,,,,,Ketamine,480,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17141,Retrospective Cohort,Slor 2011b,[Slor 2011b](evidence_tables.html#17141),[Slor 2011b](evidence_tables.html#17141) ([Kalisvaart 2005](evidence_tables.html#8574)),Slor 2011b-2,2,,,,,Ketamine,46,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17142,Retrospective Cohort,Mueller 2020b,[Mueller 2020b](evidence_tables.html#17142),[Mueller 2020b](evidence_tables.html#17142) ([Mueller 2020a](evidence_tables.html#118)),Mueller 2020b-1,1,,,,,Ketamine,558,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17142,Retrospective Cohort,Mueller 2020b,[Mueller 2020b](evidence_tables.html#17142),[Mueller 2020b](evidence_tables.html#17142) ([Mueller 2020a](evidence_tables.html#118)),Mueller 2020b-2,2,,,,,Ketamine,92,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17143,Retrospective Cohort,Weinstein 2018b,[Weinstein 2018b](evidence_tables.html#17143),[Weinstein 2018b](evidence_tables.html#17143) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018b-1,1,,,,,Ketamine,33500,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17143,Retrospective Cohort,Weinstein 2018b,[Weinstein 2018b](evidence_tables.html#17143),[Weinstein 2018b](evidence_tables.html#17143) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018b-2,2,,,,,Ketamine,3451,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17144,Retrospective Cohort,Weinstein 2018c,[Weinstein 2018c](evidence_tables.html#17144),[Weinstein 2018c](evidence_tables.html#17144) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018c-1,1,None,Control,None,None,Ketamine,31796,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17144,Retrospective Cohort,Weinstein 2018c,[Weinstein 2018c](evidence_tables.html#17144),[Weinstein 2018c](evidence_tables.html#17144) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018c-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,4070,kq6_proph_meds,,,,,,,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,intraoperative ketamine study notes,
17145,Retrospective Cohort,Weinstein 2018d,[Weinstein 2018d](evidence_tables.html#17145),[Weinstein 2018d](evidence_tables.html#17145) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018d-1,1,None,Control,None,None,Ketamine,36852,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17145,Retrospective Cohort,Weinstein 2018d,[Weinstein 2018d](evidence_tables.html#17145),[Weinstein 2018d](evidence_tables.html#17145) ([Weinstein 2018a](evidence_tables.html#4888)),Weinstein 2018d-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,99,kq6_proph_meds,,,,,,proph_med_postop,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,"postoperative ketamine; study notes ""rather large doses (i.e., averaging >1500 mg) administered""",
17146,Prospective Cohort,Ke 2022b,[Ke 2022b](evidence_tables.html#17146),[Ke 2022b](evidence_tables.html#17146) ([Ke 2022a](evidence_tables.html#6840)),Ke 2022b-1,1,None,Control,None,None,Dexmedetomidine,97,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17146,Prospective Cohort,Ke 2022b,[Ke 2022b](evidence_tables.html#17146),[Ke 2022b](evidence_tables.html#17146) ([Ke 2022a](evidence_tables.html#6840)),Ke 2022b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,1,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,,,,,,,,,,,,,,,,,,,,,,,,,not reported,
17147,Prospective Cohort,Ke 2022c,[Ke 2022c](evidence_tables.html#17147),[Ke 2022c](evidence_tables.html#17147) ([Ke 2022a](evidence_tables.html#6840)),Ke 2022c-1,1,None,Control,None,None,Ketamine,92,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17147,Prospective Cohort,Ke 2022c,[Ke 2022c](evidence_tables.html#17147),[Ke 2022c](evidence_tables.html#17147) ([Ke 2022a](evidence_tables.html#6840)),Ke 2022c-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,6,kq6_proph_meds,,,,,proph_med_intra,,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,,
17148,Retrospective Cohort,Fuchita 2019b,[Fuchita 2019b](evidence_tables.html#17148),[Fuchita 2019b](evidence_tables.html#17148) ([Fuchita 2019a](evidence_tables.html#8003)),Fuchita 2019b-1,1,,,,,Ketamine,77,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17148,Retrospective Cohort,Fuchita 2019b,[Fuchita 2019b](evidence_tables.html#17148),[Fuchita 2019b](evidence_tables.html#17148) ([Fuchita 2019a](evidence_tables.html#8003)),Fuchita 2019b-2,2,,,,,Ketamine,7,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17149,Retrospective Cohort,Fuchita 2019c,[Fuchita 2019c](evidence_tables.html#17149),[Fuchita 2019c](evidence_tables.html#17149) ([Fuchita 2019a](evidence_tables.html#8003)),Fuchita 2019c-1,1,None,Control,None,None,Ketamine,74,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17149,Retrospective Cohort,Fuchita 2019c,[Fuchita 2019c](evidence_tables.html#17149),[Fuchita 2019c](evidence_tables.html#17149) ([Fuchita 2019a](evidence_tables.html#8003)),Fuchita 2019c-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,10,kq6_proph_meds,,,,,proph_med_intra,,,,,,,,,ketamine,,,,,,,,,,,,,,,,,,,,,,
17150,Retrospective Cohort,Liu 2023b,[Liu 2023b](evidence_tables.html#17150),[Liu 2023b](evidence_tables.html#17150) ([Liu 2023a](evidence_tables.html#17038)),Liu 2023b-1,1,None,Control,None,None,Dexmedetomidine,35,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,No intraoperative dexmedetomidine
17150,Retrospective Cohort,Liu 2023b,[Liu 2023b](evidence_tables.html#17150),[Liu 2023b](evidence_tables.html#17150) ([Liu 2023a](evidence_tables.html#17038)),Liu 2023b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,160,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,,,,,,,,,,,,,,,,,,,,,,,,,intraoperative dexmedetomidine,
17152,Randomized Clinical Trial,Esmaeii 2022,[Esmaeii 2022](evidence_tables.html#17152),[Esmaeii 2022](evidence_tables.html#17152),Esmaeii 2022-1,1,None,Control,None,None,Melatonin,49,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17152,Randomized Clinical Trial,Esmaeii 2022,[Esmaeii 2022](evidence_tables.html#17152),[Esmaeii 2022](evidence_tables.html#17152),Esmaeii 2022-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,51,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,,,,,melatonin,5,2,,,,,,,,,,,,,,,A first dose of these medications was given at bedtime the night before surgery and a second dose 90 minutes before surgery.,
17153,Randomized Clinical Trial,Fazel 2022,[Fazel 2022](evidence_tables.html#17153),[Fazel 2022](evidence_tables.html#17153),Fazel 2022-1,1,Placebo,Control,Placebo,Plac,Melatonin,36,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Patients received placebo (as Avisel capsules) the night before the surgery, the night of the operation, and two nights after the surgical operation at 9pm."
17153,Randomized Clinical Trial,Fazel 2022,[Fazel 2022](evidence_tables.html#17153),[Fazel 2022](evidence_tables.html#17153),Fazel 2022-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,36,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,melatonin,5,4,,,,,,,,,,,,,,,"5 mg melatonin capsules (Now Food, Bloomingdale, IL 60108, USA) orally the night before surgery, the night of the operation, and two nights postop at 9pm.",
17154,Randomized Clinical Trial,Mohamed 2022,[Mohamed 2022](evidence_tables.html#17154),[Mohamed 2022](evidence_tables.html#17154),Mohamed 2022-1,1,Placebo,Control,Placebo,Plac,Melatonin,40,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,500 mg tablet of paracetamol as a placebo as it looks similar to melatonin tablets. They were packed in an opaque envelope and given orally at 9pm before surgery and another 500 mg with 15 mL of clear water 30 min before surgery.
17154,Randomized Clinical Trial,Mohamed 2022,[Mohamed 2022](evidence_tables.html#17154),[Mohamed 2022](evidence_tables.html#17154),Mohamed 2022-2,2,Melatonin,Melatonin,Melatonin,Mel,Melatonin,40,kq6_proph_meds,,,proph_med_pre,,,,,,,,,,,,,,,melatonin,5,2,,,,,,,,,,,,,,,"5 mg tablet of melatonin, packed in an opaque envelope, given orally at 9pm the evening before surgery and another 5 mg of melatonin with 15 mL of clear water 30 minutes before surgery.",
17155,Randomized Clinical Trial,Shyu 2008,[Shyu 2008](evidence_tables.html#17155),[Shyu 2008](evidence_tables.html#17155) ([Shyu 2005](evidence_tables.html#17156)),Shyu 2008-1,1,,,,,Melatonin,82,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17155,Randomized Clinical Trial,Shyu 2008,[Shyu 2008](evidence_tables.html#17155),[Shyu 2008](evidence_tables.html#17155) ([Shyu 2005](evidence_tables.html#17156)),Shyu 2008-2,2,,,,,Melatonin,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17156,Randomized Clinical Trial,Shyu 2005,[Shyu 2005](evidence_tables.html#17156),[Shyu 2005](evidence_tables.html#17156),Shyu 2005-1,1,,,,,Melatonin,69,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17156,Randomized Clinical Trial,Shyu 2005,[Shyu 2005](evidence_tables.html#17156),[Shyu 2005](evidence_tables.html#17156),Shyu 2005-2,2,,,,,Melatonin,68,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17228,Retrospective Cohort,Poeran 2020a,[Poeran 2020a](evidence_tables.html#17228),[Poeran 2020a](evidence_tables.html#17228),Poeran 2020a-1,1,,,,,Melatonin,338015,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17228,Retrospective Cohort,Poeran 2020a,[Poeran 2020a](evidence_tables.html#17228),[Poeran 2020a](evidence_tables.html#17228),Poeran 2020a-2,2,,,,,Melatonin,167137,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17365,Randomized Clinical Trial,Brondum 2022,[Brondum 2022](evidence_tables.html#17365),[Brondum 2022](evidence_tables.html#17365),Brondum 2022-1,1,,,,,Melatonin,16,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17365,Randomized Clinical Trial,Brondum 2022,[Brondum 2022](evidence_tables.html#17365),[Brondum 2022](evidence_tables.html#17365),Brondum 2022-2,2,,,,,Melatonin,17,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17503,Randomized Clinical Trial,Gao 2022,[Gao 2022](evidence_tables.html#17503),[Gao 2022](evidence_tables.html#17503),Gao 2022-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,48,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline at induction and infusion of 0.4 mcg/kg/h during surgery
17503,Randomized Clinical Trial,Gao 2022,[Gao 2022](evidence_tables.html#17503),[Gao 2022](evidence_tables.html#17503),Gao 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,47,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,proph_med_postop,,dexmedetomidine,1,0.4,,,2,,,,,,,,,,,,,,,,,,,,,,postoperative dose 2 mcg/kg,
17531,Randomized Clinical Trial,Guo 2022,[Guo 2022](evidence_tables.html#17531),[Guo 2022](evidence_tables.html#17531),Guo 2022-1,1,None,Control,None,None,Dexmedetomidine,45,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17531,Randomized Clinical Trial,Guo 2022,[Guo 2022](evidence_tables.html#17531),[Guo 2022](evidence_tables.html#17531),Guo 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,45,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.5,,,,,,,,,,,,,,,,,,,,,,,,,,
17551,Retrospective Cohort,Hasselager 2022,[Hasselager 2022](evidence_tables.html#17551),[Hasselager 2022](evidence_tables.html#17551),Hasselager 2022-1,1,,,,,Dexmedetomidine,8722,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17551,Retrospective Cohort,Hasselager 2022,[Hasselager 2022](evidence_tables.html#17551),[Hasselager 2022](evidence_tables.html#17551),Hasselager 2022-2,2,,,,,Dexmedetomidine,8722,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17575,Randomized Clinical Trial,Hu 2022,[Hu 2022](evidence_tables.html#17575),[Hu 2022](evidence_tables.html#17575),Hu 2022-1,1,None,Control,None,None,Dexmedetomidine,20,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17575,Randomized Clinical Trial,Hu 2022,[Hu 2022](evidence_tables.html#17575),[Hu 2022](evidence_tables.html#17575),Hu 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,20,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,,0.4,,,,,,,,,,,,,,,,,,,,,,,,,loading dose 0.04 mg/ml,
17683,Randomized Clinical Trial,Kowalczyk 2022,[Kowalczyk 2022](evidence_tables.html#17683),[Kowalczyk 2022](evidence_tables.html#17683),Kowalczyk 2022-1,1,None,Control,None,None,Dexmedetomidine,23,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17683,Randomized Clinical Trial,Kowalczyk 2022,[Kowalczyk 2022](evidence_tables.html#17683),[Kowalczyk 2022](evidence_tables.html#17683),Kowalczyk 2022-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,23,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,0.25,,,,,,,,,,,,,,,,,,,,,,,,,,
17971,Randomized Clinical Trial,Sciberras 2022,[Sciberras 2022](evidence_tables.html#17971),[Sciberras 2022](evidence_tables.html#17971),Sciberras 2022-1,1,,,,,Dexmedetomidine,101,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17971,Randomized Clinical Trial,Sciberras 2022,[Sciberras 2022](evidence_tables.html#17971),[Sciberras 2022](evidence_tables.html#17971),Sciberras 2022-2,2,,,,,Dexmedetomidine,99,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17987,Randomized Clinical Trial,Shen 2022,[Shen 2022](evidence_tables.html#17987),[Shen 2022](evidence_tables.html#17987),Shen 2022-1,1,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17987,Randomized Clinical Trial,Shen 2022,[Shen 2022](evidence_tables.html#17987),[Shen 2022](evidence_tables.html#17987),Shen 2022-2,2,,,,,Dexmedetomidine,60,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18152,Randomized Clinical Trial,Yang 2022,[Yang 2022](evidence_tables.html#18152),[Yang 2022](evidence_tables.html#18152),Yang 2022-1,1,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18152,Randomized Clinical Trial,Yang 2022,[Yang 2022](evidence_tables.html#18152),[Yang 2022](evidence_tables.html#18152),Yang 2022-2,2,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18178,Randomized Clinical Trial,Zeng 2022,[Zeng 2022](evidence_tables.html#18178),[Zeng 2022](evidence_tables.html#18178),Zeng 2022-1,1,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18178,Randomized Clinical Trial,Zeng 2022,[Zeng 2022](evidence_tables.html#18178),[Zeng 2022](evidence_tables.html#18178),Zeng 2022-2,2,,,,,Dexmedetomidine,30,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18346,Randomized Clinical Trial,Deng 2023,[Deng 2023](evidence_tables.html#18346),[Deng 2023](evidence_tables.html#18346),Deng 2023-1,1,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,53,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,0.2,0.7,,,,,,,,,,,,,,,,,,,,Dexmedetomidine,,,sedation given based on patient's demand with dexmedetomidine,
18346,Randomized Clinical Trial,Deng 2023,[Deng 2023](evidence_tables.html#18346),[Deng 2023](evidence_tables.html#18346),Deng 2023-2,2,Remimazolam,Remimazolam,Remimazolam,Rem,Remimazolam,52,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Remimazolam,,,,
18378,Randomized Clinical Trial,Farrer 2023,[Farrer 2023](evidence_tables.html#18378),[Farrer 2023](evidence_tables.html#18378),Farrer 2023-1,1,,,,,Remimazolam,99,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18378,Randomized Clinical Trial,Farrer 2023,[Farrer 2023](evidence_tables.html#18378),[Farrer 2023](evidence_tables.html#18378),Farrer 2023-2,2,,,,,Remimazolam,100,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18435,Randomized Clinical Trial,Han 2023,[Han 2023](evidence_tables.html#18435),[Han 2023](evidence_tables.html#18435),Han 2023-1,1,Placebo,Control,Placebo,Plac,Ketamine,34,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(0.15 mg/kg) intravenous saline 5 minutes before the initiation of surgery
18435,Randomized Clinical Trial,Han 2023,[Han 2023](evidence_tables.html#18435),[Han 2023](evidence_tables.html#18435),Han 2023-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,33,kq6_proph_meds,,,,proph_med_induct,,,,,,,,,,ketamine,0.15,,,,,,,,,,,,,,,,,,,,Esketamine group was intravenously instilled with 0.15 mg/kg esketamine 5 min before the beginning of the surgery.,
18474,Randomized Clinical Trial,Huang 2023a,[Huang 2023a](evidence_tables.html#18474),[Huang 2023a](evidence_tables.html#18474),Huang 2023a-1,1,,,,,Ketamine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18474,Randomized Clinical Trial,Huang 2023a,[Huang 2023a](evidence_tables.html#18474),[Huang 2023a](evidence_tables.html#18474),Huang 2023a-2,2,,,,,Ketamine,80,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18477,Retrospective Cohort,Huang 2023b,[Huang 2023b](evidence_tables.html#18477),[Huang 2023b](evidence_tables.html#18477),Huang 2023b-1,1,,,,,Ketamine,26,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18477,Retrospective Cohort,Huang 2023b,[Huang 2023b](evidence_tables.html#18477),[Huang 2023b](evidence_tables.html#18477),Huang 2023b-2,2,,,,,Ketamine,20,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18509,Retrospective Cohort,Kaneko 2023,[Kaneko 2023](evidence_tables.html#18509),[Kaneko 2023](evidence_tables.html#18509),Kaneko 2023-1,1,,,,,Ketamine,58,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18509,Retrospective Cohort,Kaneko 2023,[Kaneko 2023](evidence_tables.html#18509),[Kaneko 2023](evidence_tables.html#18509),Kaneko 2023-2,2,,,,,Ketamine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18510,Randomized Clinical Trial,Kang 2023,[Kang 2023](evidence_tables.html#18510),[Kang 2023](evidence_tables.html#18510),Kang 2023-1,1,,,,,Ketamine,48,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18510,Randomized Clinical Trial,Kang 2023,[Kang 2023](evidence_tables.html#18510),[Kang 2023](evidence_tables.html#18510),Kang 2023-2,2,,,,,Ketamine,47,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18530,Randomized Clinical Trial,Kinouchi 2023,[Kinouchi 2023](evidence_tables.html#18530),[Kinouchi 2023](evidence_tables.html#18530),Kinouchi 2023-1,1,Placebo,Control,Placebo,Plac,Ramelteon,49,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8 mg lactose pill on the preop night and 5 days post op
18530,Randomized Clinical Trial,Kinouchi 2023,[Kinouchi 2023](evidence_tables.html#18530),[Kinouchi 2023](evidence_tables.html#18530),Kinouchi 2023-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,54,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,8,6,,,,,,,,,,,,8 mg pill on the preop night and 5 days post op,
18548,Randomized Clinical Trial,Kuang 2023,[Kuang 2023](evidence_tables.html#18548),[Kuang 2023](evidence_tables.html#18548),Kuang 2023-1,1,,,,,Ramelteon,42,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18548,Randomized Clinical Trial,Kuang 2023,[Kuang 2023](evidence_tables.html#18548),[Kuang 2023](evidence_tables.html#18548),Kuang 2023-2,2,,,,,Ramelteon,42,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18558,Randomized Clinical Trial,Lai 2023,[Lai 2023](evidence_tables.html#18558),[Lai 2023](evidence_tables.html#18558),Lai 2023-1,1,None,Control,None,None,Dexmedetomidine,30,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18558,Randomized Clinical Trial,Lai 2023,[Lai 2023](evidence_tables.html#18558),[Lai 2023](evidence_tables.html#18558),Lai 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,29,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,1,0.5,,,,,,,,,,,,,,,,,,,,,,,,,induction dose=1.0 mcg/kg/h for 10 minutes,
18575,Randomized Clinical Trial,Li 2023,[Li 2023](evidence_tables.html#18575),[Li 2023](evidence_tables.html#18575),Li 2023-1,1,None,Control,None,None,Dexmedetomidine,49,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18575,Randomized Clinical Trial,Li 2023,[Li 2023](evidence_tables.html#18575),[Li 2023](evidence_tables.html#18575),Li 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,49,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,4,0.2,,,,,,,,,,,,,,,,,,,,,,,,,loading dose = 4 mcg/mL for 10 min,
18582,Randomized Clinical Trial,Liao 2023,[Liao 2023](evidence_tables.html#18582),[Liao 2023](evidence_tables.html#18582),Liao 2023-1,1,Placebo,Control,Placebo,Plac,Remimazolam,35,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Placebo,Saline,,,Saline
18582,Randomized Clinical Trial,Liao 2023,[Liao 2023](evidence_tables.html#18582),[Liao 2023](evidence_tables.html#18582),Liao 2023-2,2,Remimazolam,Remimazolam,Remimazolam,Rem,Remimazolam,34,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Remimazolam,,,,
18582,Randomized Clinical Trial,Liao 2023,[Liao 2023](evidence_tables.html#18582),[Liao 2023](evidence_tables.html#18582),Liao 2023-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,35,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,,0.3,0.5,,,,,,,,,,,,,,,,,,,,Dexmedetomidine,,,,
18597,Randomized Clinical Trial,Liu 2023c,[Liu 2023c](evidence_tables.html#18597),[Liu 2023c](evidence_tables.html#18597),Liu 2023c-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,149,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 mcg/kg bolus of saline placebo was administered for 10 min followed by a maintenance infusion of 0.2 mcg/kg/hr until the end of surgery
18597,Randomized Clinical Trial,Liu 2023c,[Liu 2023c](evidence_tables.html#18597),[Liu 2023c](evidence_tables.html#18597),Liu 2023c-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,150,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.5,0.2,,,,,,,,,,,,,,,,,,,,,,,,,0.5 mcg/kg bolus of dexmedetomidine placebo was administered for 10 min followed by a maintenance infusion of 0.2 mcg/kg/hr until the end of surgery,
18610,Randomized Clinical Trial,Ma 2023,[Ma 2023](evidence_tables.html#18610),[Ma 2023](evidence_tables.html#18610),Ma 2023-1,1,Placebo,Control,Placebo,Plac,Ketamine,31,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline administered during surgery
18610,Randomized Clinical Trial,Ma 2023,[Ma 2023](evidence_tables.html#18610),[Ma 2023](evidence_tables.html#18610),Ma 2023-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,31,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,,,,,,,ketamine,0.25,0.125,,,,,,,,,,,,,,,,,,,esketamine administered during surgery,
18678,Randomized Clinical Trial,O'Brien 2023 (no dementia),[O'Brien 2023 (no dementia)](evidence_tables.html#18678),[O'Brien 2023 (no dementia)](evidence_tables.html#18678),O'Brien 2023-1,1,,,,,Ketamine,418,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18678,Randomized Clinical Trial,O'Brien 2023 (no dementia),[O'Brien 2023 (no dementia)](evidence_tables.html#18678),[O'Brien 2023 (no dementia)](evidence_tables.html#18678),O'Brien 2023-2,2,,,,,Ketamine,408,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18678,Randomized Clinical Trial,O'Brien 2023 (dementia),[O'Brien 2023 (dementia)](evidence_tables.html#18678),[O'Brien 2023 (dementia)](evidence_tables.html#18678),O'Brien 2023-3,3,,,,,Ketamine,211,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18678,Randomized Clinical Trial,O'Brien 2023 (dementia),[O'Brien 2023 (dementia)](evidence_tables.html#18678),[O'Brien 2023 (dementia)](evidence_tables.html#18678),O'Brien 2023-4,4,,,,,Ketamine,225,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18690,Randomized Clinical Trial,Oriby 2023,[Oriby 2023](evidence_tables.html#18690),[Oriby 2023](evidence_tables.html#18690),Oriby 2023-1,1,Placebo,Control,Placebo,Plac,Ketamine,30,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cataract extraction under peribulbar block,,,,,,Normal saline by continuous infusion as a placebo. Medications were administered by intravenous infusion and started 10 min before the surgery and continued throughout the duration of surgery.
18690,Randomized Clinical Trial,Oriby 2023,[Oriby 2023](evidence_tables.html#18690),[Oriby 2023](evidence_tables.html#18690),Oriby 2023-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,,,,,,,ketamine,,0.3,,,,,,,,,,,,,,cataract extraction under peribulbar block,,,,,0.3 mg/kg/h of ketamine. Medications were administrated by intravenous infusion and started 10 min before the surgery and continued throughout the duration of surgery.,
18690,Randomized Clinical Trial,Oriby 2023,[Oriby 2023](evidence_tables.html#18690),[Oriby 2023](evidence_tables.html#18690),Oriby 2023-3,3,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,30,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,,0.5,,,,,,0.3,,,,,,,,,,,,,,cataract extraction under peribulbar block,,,,,0.5 mcg/kg/hr of dexmedetomidine. Medications were administrated by intravenous infusion and started 10 min before the surgery and continued throughout the duration of surgery.,
18797,Before-After/Time Series,Smoor 2023,[Smoor 2023](evidence_tables.html#18797),[Smoor 2023](evidence_tables.html#18797),Smoor 2023-1,1,,,,,Ketamine,183,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18797,Before-After/Time Series,Smoor 2023,[Smoor 2023](evidence_tables.html#18797),[Smoor 2023](evidence_tables.html#18797),Smoor 2023-2,2,,,,,Ketamine,183,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18807,Before-After/Time Series,Staiger 2023,[Staiger 2023](evidence_tables.html#18807),[Staiger 2023](evidence_tables.html#18807),Staiger 2023-1,1,,,,,Ketamine,54,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18807,Before-After/Time Series,Staiger 2023,[Staiger 2023](evidence_tables.html#18807),[Staiger 2023](evidence_tables.html#18807),Staiger 2023-2,2,,,,,Ketamine,18,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18819,Prospective Cohort,Sun 2023a,[Sun 2023a](evidence_tables.html#18819),[Sun 2023a](evidence_tables.html#18819),Sun 2023a-1,1,None,Control,None,None,Dexmedetomidine,289,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18819,Prospective Cohort,Sun 2023a,[Sun 2023a](evidence_tables.html#18819),[Sun 2023a](evidence_tables.html#18819),Sun 2023a-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,354,kq6_proph_meds,,,,,,,proph_med_unspec,dexmedetomidine,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18820,Randomized Clinical Trial,Sun 2023b,[Sun 2023b](evidence_tables.html#18820),[Sun 2023b](evidence_tables.html#18820),Sun 2023b-1,1,,,,,Dexmedetomidine,51,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18820,Randomized Clinical Trial,Sun 2023b,[Sun 2023b](evidence_tables.html#18820),[Sun 2023b](evidence_tables.html#18820),Sun 2023b-2,2,,,,,Dexmedetomidine,53,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18867,Randomized Clinical Trial,Villalobos 2023,[Villalobos 2023](evidence_tables.html#18867),[Villalobos 2023](evidence_tables.html#18867),Villalobos 2023-1,1,,,,,Dexmedetomidine,54,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18867,Randomized Clinical Trial,Villalobos 2023,[Villalobos 2023](evidence_tables.html#18867),[Villalobos 2023](evidence_tables.html#18867),Villalobos 2023-2,2,,,,,Dexmedetomidine,53,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18870,Randomized Clinical Trial,Racman 2023,[Racman 2023](evidence_tables.html#18870),[Racman 2023](evidence_tables.html#18870),Racman 2023-1,1,Other,Control,Propofol,Prop,Dexmedetomidine,34,kq6_no_proph_meds,kq6_other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propofol,,0.5-2.5 mg/kg/h propofol by continuous intravenous infusion
18870,Randomized Clinical Trial,Racman 2023,[Racman 2023](evidence_tables.html#18870),[Racman 2023](evidence_tables.html#18870),Racman 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,37,kq6_proph_meds,,,,proph_med_induct,proph_med_intra,,,dexmedetomidine,0.5,,0.2,1,,,,,,,,,,,,,,,,,,,,,,,,
18909,Randomized Clinical Trial,Xie 2023,[Xie 2023](evidence_tables.html#18909),[Xie 2023](evidence_tables.html#18909),Xie 2023-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,119,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Postop PCIA pump of 3 mcg/kg sufentanil
18909,Randomized Clinical Trial,Xie 2023,[Xie 2023](evidence_tables.html#18909),[Xie 2023](evidence_tables.html#18909),Xie 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,117,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,,,3,,,,,,,,,,,,,,,,,,,,,,"Post op PCI pump of 3 mcg/kg sufentanil and 3 mcg/kg of DEX. The PCIA parameters were programmed as follows: total amount 150ml, 2 ml bolus dose with a lock-out of 10 min and background infusion rate 2ml/h.",
18927,Randomized Clinical Trial,Yang 2023,[Yang 2023](evidence_tables.html#18927),[Yang 2023](evidence_tables.html#18927),Yang 2023-1,1,,,,,Dexmedetomidine,153,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18927,Randomized Clinical Trial,Yang 2023,[Yang 2023](evidence_tables.html#18927),[Yang 2023](evidence_tables.html#18927),Yang 2023-2,2,,,,,Dexmedetomidine,147,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18937,Randomized Clinical Trial,Yoo 2023,[Yoo 2023](evidence_tables.html#18937),[Yoo 2023](evidence_tables.html#18937),Yoo 2023-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,64,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saline infusion during surgery
18937,Randomized Clinical Trial,Yoo 2023,[Yoo 2023](evidence_tables.html#18937),[Yoo 2023](evidence_tables.html#18937),Yoo 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,64,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,1,0.2,,,,,,,,,,,,,,,,,,,,,,,,,dexmedetomidine infusion during surgery,
18938,Retrospective Cohort,Yoshimura 2023,[Yoshimura 2023](evidence_tables.html#18938),[Yoshimura 2023](evidence_tables.html#18938),Yoshimura 2023-1,1,,,,,Dexmedetomidine,5552,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18938,Retrospective Cohort,Yoshimura 2023,[Yoshimura 2023](evidence_tables.html#18938),[Yoshimura 2023](evidence_tables.html#18938),Yoshimura 2023-2,2,,,,,Dexmedetomidine,10633,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18945,Retrospective Cohort,Zarour 2023,[Zarour 2023](evidence_tables.html#18945),[Zarour 2023](evidence_tables.html#18945),Zarour 2023-1,1,,,,,Dexmedetomidine,1191,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18945,Retrospective Cohort,Zarour 2023,[Zarour 2023](evidence_tables.html#18945),[Zarour 2023](evidence_tables.html#18945),Zarour 2023-2,2,,,,,Dexmedetomidine,782,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18958,Randomized Clinical Trial,Zhao 2023,[Zhao 2023](evidence_tables.html#18958),[Zhao 2023](evidence_tables.html#18958),Zhao 2023-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,42,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Normal saline
18958,Randomized Clinical Trial,Zhao 2023,[Zhao 2023](evidence_tables.html#18958),[Zhao 2023](evidence_tables.html#18958),Zhao 2023-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,40,kq6_proph_meds,,,,,,proph_med_postop,,dexmedetomidine,,,,,200,,,,,,,,,,,,,,,,,,,,,,one dose of dex 200 ug/2 ml,
18976,Retrospective Cohort,Poeran 2020b,[Poeran 2020b](evidence_tables.html#18976),[Poeran 2020b](evidence_tables.html#18976) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020b-1,1,,,,,Dexmedetomidine,480056,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18976,Retrospective Cohort,Poeran 2020b,[Poeran 2020b](evidence_tables.html#18976),[Poeran 2020b](evidence_tables.html#18976) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020b-2,2,,,,,Dexmedetomidine,25096,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18977,Retrospective Cohort,Poeran 2020c,[Poeran 2020c](evidence_tables.html#18977),[Poeran 2020c](evidence_tables.html#18977) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020c-1,1,,,,,Dexmedetomidine,436131,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18977,Retrospective Cohort,Poeran 2020c,[Poeran 2020c](evidence_tables.html#18977),[Poeran 2020c](evidence_tables.html#18977) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020c-2,2,,,,,Dexmedetomidine,69021,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18978,Retrospective Cohort,Poeran 2020d,[Poeran 2020d](evidence_tables.html#18978),[Poeran 2020d](evidence_tables.html#18978) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020d-1,1,None,Control,None,None,Ketamine,468004,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18978,Retrospective Cohort,Poeran 2020d,[Poeran 2020d](evidence_tables.html#18978),[Poeran 2020d](evidence_tables.html#18978) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020d-2,2,Ketamine,Ketamine,Ketamine,Ket,Ketamine,37148,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,ketamine,,,,,,,,,,,,,,,,no details on dosing reported,,,,,,
18979,Retrospective Cohort,Poeran 2020e,[Poeran 2020e](evidence_tables.html#18979),[Poeran 2020e](evidence_tables.html#18979) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020e-1,1,None,Control,None,None,Gabapentin,467371,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18979,Retrospective Cohort,Poeran 2020e,[Poeran 2020e](evidence_tables.html#18979),[Poeran 2020e](evidence_tables.html#18979) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020e-2,2,Gabapentin,Gabapentin,Gabapentin,Gab,Gabapentin,37781,kq6_proph_meds,,,proph_med_pre,,,proph_med_postop,,,,,,,,,,,,,,,,,,gabapentin,,,,,,,,,,,,
18983,Retrospective Cohort,Poeran 2020f,[Poeran 2020f](evidence_tables.html#18983),[Poeran 2020f](evidence_tables.html#18983) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020f-1,1,,,,,Gabapentin,450479,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18983,Retrospective Cohort,Poeran 2020f,[Poeran 2020f](evidence_tables.html#18983),[Poeran 2020f](evidence_tables.html#18983) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020f-2,2,,,,,Gabapentin,54673,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18984,Retrospective Cohort,Poeran 2020g,[Poeran 2020g](evidence_tables.html#18984),[Poeran 2020g](evidence_tables.html#18984) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020g-1,1,,,,,Gabapentin,455116,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18984,Retrospective Cohort,Poeran 2020g,[Poeran 2020g](evidence_tables.html#18984),[Poeran 2020g](evidence_tables.html#18984) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020g-2,2,,,,,Gabapentin,50036,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18985,Retrospective Cohort,Poeran 2020h,[Poeran 2020h](evidence_tables.html#18985),[Poeran 2020h](evidence_tables.html#18985) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020h-1,1,,,,,Gabapentin,484190,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18985,Retrospective Cohort,Poeran 2020h,[Poeran 2020h](evidence_tables.html#18985),[Poeran 2020h](evidence_tables.html#18985) ([Poeran 2020a](evidence_tables.html#17228)),Poeran 2020h-2,2,,,,,Gabapentin,20962,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18986,Retrospective Cohort,Chang 2024,[Chang 2024](evidence_tables.html#18986),[Chang 2024](evidence_tables.html#18986),Chang 2024-1,1,,,,,Gabapentin,140,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18986,Retrospective Cohort,Chang 2024,[Chang 2024](evidence_tables.html#18986),[Chang 2024](evidence_tables.html#18986),Chang 2024-2,2,,,,,Gabapentin,141,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18987,Randomized Clinical Trial,Mei 2020b,[Mei 2020b](evidence_tables.html#18987),[Mei 2020b](evidence_tables.html#18987),Mei 2020b-1,1,,,,,Gabapentin,103,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18987,Randomized Clinical Trial,Mei 2020b,[Mei 2020b](evidence_tables.html#18987),[Mei 2020b](evidence_tables.html#18987),Mei 2020b-2,2,,,,,Gabapentin,106,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19171,Before-After/Time Series,Harari 2007,[Harari 2007](evidence_tables.html#19171),[Harari 2007](evidence_tables.html#19171),Harari 2007-1,1,,,,,Gabapentin,54,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19171,Before-After/Time Series,Harari 2007,[Harari 2007](evidence_tables.html#19171),[Harari 2007](evidence_tables.html#19171),Harari 2007-2,2,,,,,Gabapentin,54,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19377,Retrospective Cohort,Paille 2021,[Paille 2021](evidence_tables.html#19377),[Paille 2021](evidence_tables.html#19377),Paille 2021-1,1,,,,,Gabapentin,114,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19377,Retrospective Cohort,Paille 2021,[Paille 2021](evidence_tables.html#19377),[Paille 2021](evidence_tables.html#19377),Paille 2021-2,2,,,,,Gabapentin,114,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20083,Randomized Clinical Trial,Kalimeris 2013,[Kalimeris 2013](evidence_tables.html#20083),[Kalimeris 2013](evidence_tables.html#20083),Kalimeris 2013-1,1,,,,,Gabapentin,21,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20083,Randomized Clinical Trial,Kalimeris 2013,[Kalimeris 2013](evidence_tables.html#20083),[Kalimeris 2013](evidence_tables.html#20083),Kalimeris 2013-2,2,,,,,Gabapentin,23,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20412,Randomized Clinical Trial,Tian 2021,[Tian 2021](evidence_tables.html#20412),[Tian 2021](evidence_tables.html#20412),Tian 2021-1,1,,,,,Gabapentin,31,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20412,Randomized Clinical Trial,Tian 2021,[Tian 2021](evidence_tables.html#20412),[Tian 2021](evidence_tables.html#20412),Tian 2021-2,2,,,,,Gabapentin,31,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20438,Retrospective Cohort,Ishibashi-Kanno 2020a,[Ishibashi-Kanno 2020a](evidence_tables.html#20438),[Ishibashi-Kanno 2020a](evidence_tables.html#20438),Ishibashi-Kanno 2020a-1,1,None,Control,None,None,Ramelteon,34,kq6_no_proph_meds,kq6_none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20438,Retrospective Cohort,Ishibashi-Kanno 2020a,[Ishibashi-Kanno 2020a](evidence_tables.html#20438),[Ishibashi-Kanno 2020a](evidence_tables.html#20438),Ishibashi-Kanno 2020a-2,2,Ramelteon,Ramelteon,Ramelteon,Ram,Ramelteon,35,kq6_proph_meds,,,,,,proph_med_postop,,,,,,,,,,,,,,,ramelteon,,,,,,,,,,,,,,,
20454,Randomized Clinical Trial,Soh 2020,[Soh 2020](evidence_tables.html#20454),[Soh 2020](evidence_tables.html#20454),Soh 2020-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,54,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Received an infusion of an equivalent volume of 0/9% saline for the same duration.
20454,Randomized Clinical Trial,Soh 2020,[Soh 2020](evidence_tables.html#20454),[Soh 2020](evidence_tables.html#20454),Soh 2020-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,54,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,,,0.4,,,,,,,,,,,,,,,,,,,,,,,,"Dexmedetomidine 200mcg was mixed with 0.9% saline to achieve a concentration of 4 mcg/ml, which was continuously infused at a rate of 0.4 mcg/kg/h for 24 hours starting immediately after anesthetic induction.",
20465,Randomized Clinical Trial,Li 2020b,[Li 2020b](evidence_tables.html#20465),[Li 2020b](evidence_tables.html#20465),Li 2020b-1,1,Placebo,Control,Placebo,Plac,Dexmedetomidine,310,kq6_no_proph_meds,kq6_placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Volume-matched normal saline was administered at the same rate for the same duration
20465,Randomized Clinical Trial,Li 2020b,[Li 2020b](evidence_tables.html#20465),[Li 2020b](evidence_tables.html#20465),Li 2020b-2,2,Dexmedetomidine,Dexmedetomidine,Dexmedetomidine,Dex,Dexmedetomidine,309,kq6_proph_meds,,,,,proph_med_intra,,,dexmedetomidine,0.6,0.5,,,,,,,,,,,,,,,,,,,,,,,,,"loading dose of dexmedetomidine (0.6 mcg/kg) was administered over a 10 min period  before induction of anaesthesia, followed by a continuous infusion at a rate of (0.5 mcg per kg per h) until 1 hour before the end of the surgery.",
20581,Randomized Clinical Trial,Valentin 2016,[Valentin 2016](evidence_tables.html#20581),[Valentin 2016](evidence_tables.html#20581),Valentin 2016-1,1,,,,,Dexmedetomidine,40,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20581,Randomized Clinical Trial,Valentin 2016,[Valentin 2016](evidence_tables.html#20581),[Valentin 2016](evidence_tables.html#20581),Valentin 2016-2,2,,,,,Dexmedetomidine,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20764,Retrospective Cohort,Kadoi 2007,[Kadoi 2007](evidence_tables.html#20764),[Kadoi 2007](evidence_tables.html#20764),Kadoi 2007-1,1,,,,,Dexmedetomidine,58,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20764,Retrospective Cohort,Kadoi 2007,[Kadoi 2007](evidence_tables.html#20764),[Kadoi 2007](evidence_tables.html#20764),Kadoi 2007-2,2,,,,,Dexmedetomidine,48,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20892,Retrospective Cohort,Memtsoudis 2019k,[Memtsoudis 2019k](evidence_tables.html#20892),[Memtsoudis 2019k](evidence_tables.html#20892) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019k-1,1,,,,,Dexmedetomidine,428543,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20892,Retrospective Cohort,Memtsoudis 2019k,[Memtsoudis 2019k](evidence_tables.html#20892),[Memtsoudis 2019k](evidence_tables.html#20892) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019k-2,2,,,,,Dexmedetomidine,135683,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20893,Retrospective Cohort,Memtsoudis 2019l,[Memtsoudis 2019l](evidence_tables.html#20893),[Memtsoudis 2019l](evidence_tables.html#20893) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019l-1,1,,,,,Dexmedetomidine,861439,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20893,Retrospective Cohort,Memtsoudis 2019l,[Memtsoudis 2019l](evidence_tables.html#20893),[Memtsoudis 2019l](evidence_tables.html#20893) ([Memtsoudis 2019a](evidence_tables.html#5163)),Memtsoudis 2019l-2,2,,,,,Dexmedetomidine,269130,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20894,Retrospective Cohort,Mangusan 2015b,[Mangusan 2015b](evidence_tables.html#20894),[Mangusan 2015b](evidence_tables.html#20894) ([Mangusan 2015a](evidence_tables.html#3727)),Mangusan 2015b-1,1,,,,,Dexmedetomidine,369,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20894,Retrospective Cohort,Mangusan 2015b,[Mangusan 2015b](evidence_tables.html#20894),[Mangusan 2015b](evidence_tables.html#20894) ([Mangusan 2015a](evidence_tables.html#3727)),Mangusan 2015b-2,2,,,,,Dexmedetomidine,287,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20895,Retrospective Cohort,Mangusan 2015c,[Mangusan 2015c](evidence_tables.html#20895),[Mangusan 2015c](evidence_tables.html#20895) ([Mangusan 2015a](evidence_tables.html#3727)),Mangusan 2015c-1,1,,,,,Dexmedetomidine,620,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20895,Retrospective Cohort,Mangusan 2015c,[Mangusan 2015c](evidence_tables.html#20895),[Mangusan 2015c](evidence_tables.html#20895) ([Mangusan 2015a](evidence_tables.html#3727)),Mangusan 2015c-2,2,,,,,Dexmedetomidine,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20896,Retrospective Cohort,Ishibashi-Kanno 2020b,[Ishibashi-Kanno 2020b](evidence_tables.html#20896),[Ishibashi-Kanno 2020b](evidence_tables.html#20896) ([Ishibashi-Kanno 2020a](evidence_tables.html#20438)),Ishibashi-Kanno 2020b-1,1,,,,,Dexmedetomidine,33,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20896,Retrospective Cohort,Ishibashi-Kanno 2020b,[Ishibashi-Kanno 2020b](evidence_tables.html#20896),[Ishibashi-Kanno 2020b](evidence_tables.html#20896) ([Ishibashi-Kanno 2020a](evidence_tables.html#20438)),Ishibashi-Kanno 2020b-2,2,,,,,Dexmedetomidine,36,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20897,Retrospective Cohort,Ishibashi-Kanno 2020c,[Ishibashi-Kanno 2020c](evidence_tables.html#20897),[Ishibashi-Kanno 2020c](evidence_tables.html#20897) ([Ishibashi-Kanno 2020a](evidence_tables.html#20438)),Ishibashi-Kanno 2020c-1,1,,,,,Dexmedetomidine,37,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20897,Retrospective Cohort,Ishibashi-Kanno 2020c,[Ishibashi-Kanno 2020c](evidence_tables.html#20897),[Ishibashi-Kanno 2020c](evidence_tables.html#20897) ([Ishibashi-Kanno 2020a](evidence_tables.html#20438)),Ishibashi-Kanno 2020c-2,2,,,,,Dexmedetomidine,32,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20898,Randomized Clinical Trial,Kowark 2024,[Kowark 2024](evidence_tables.html#20898),[Kowark 2024](evidence_tables.html#20898),Kowark 2024-1,1,,,,,Dexmedetomidine,303,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20898,Randomized Clinical Trial,Kowark 2024,[Kowark 2024](evidence_tables.html#20898),[Kowark 2024](evidence_tables.html#20898),Kowark 2024-2,2,,,,,Dexmedetomidine,304,kq5_arm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
